Certification Standards for Pharmaceutical Excipient Suppliers:

Good Manufacturing Practices
Good Distribution Practices

Requirements for Auditor Competency and 3rd Party Audit Organizations Providing Certification of the Management System

minimize risks, maximize benefits
| 5 | Management responsibility | 39 |
| 6 | Resource management       | 41 |
| 7 | Product realization       | 45 |
| 8 | Measurement, analysis and improvement | 49 |

### Requirements for Auditor Qualification and Auditing Excipient Suppliers: Introduction

| 1 | Scope | 55 |
| 2 | Normative references | 55 |
| 3 | Terms and Definitions | 55 |
| 4 | Principles of Auditing | 55 |
| 5 | Managing an Audit Programme | 56 |
| 6 | Audit activities | 57 |
| 7 | Competence and Evaluation of Auditors | 61 |

### Requirements for Auditor Qualification and Auditing Excipient Suppliers: Appendix

Section 1 General | 69

Section 2 Study Guide - Professional/Work Based Experience and Training | 69

### Conformity Assessment Requirements for Certification Bodies:

**Foreword** | 74

| 1 | Scope | 75 |
| 2 | Normative References | 75 |
| 3 | Terms and definitions | 75 |
| 4 | Principles | 75 |
| 5 | General requirements | 75 |
| 6 | Structural requirements | 76 |
| 7 | Resource Requirements | 77 |
| 8 | Information requirements | 78 |
| 9 | Process Requirements | 80 |
| 10 | Management system requirements for certification bodies | 87 |

**Definitions** | 88

**References** | 94
Dedication
This document is dedicated to the memory of Dr Arnulf Heubner who until his untimely death in November 2009 was Senior Director Pharma Raw Materials, Performance and Life Science Chemicals at Merck KGaA, Darmstadt, Germany, a founder member of the EXCiPACT™ project, a Board Member of the European Fine Chemicals Group (EFCG) and Chairman of their Pharmaceuticals Business Committee. His knowledge, wisdom and enthusiasm are greatly missed.
Foreword

The safety of medicines for patients is paramount to all; the pharmaceutical industry, suppliers of raw materials, national and regional health care agencies, care givers and regulators. To assure the quality of medicines produced, risks in the supply chain need to be evaluated and minimized, and this includes the manufacture and distribution of excipients.

A great many different excipients are used in medicines and on average over 80% of each medicinal product comprise excipients. The global excipient market value is estimated to be €3bn., accounting for 0.5% of the total pharmaceutical market according to industry experts. However, few excipients are manufactured solely for pharmaceutical use.

With proposed legislation requiring GMP and GDP for excipients in Europe and enforcement of the existing legislation more prominent in the USA\(^1\), excipient suppliers will be faced with an avalanche of customer and customer driven 3rd party audits to ensure they and their products meet these new requirements. Excipient suppliers, distributors and the pharmaceutical industry are committed to ensuring the quality of excipients raw materials throughout the supply chain and aim to control this by self-regulation.

As a result, a group of industry experts from European Fine Chemical Group (EFCG), International Pharmaceutical Excipients Council (IPEC) Europe, IPEC Americas, European Association of Chemical Distributors (FECC), and Pharmaceutical Quality Group (PQG) have worked together on the development of a certification scheme for excipient suppliers – EXCiPACT™.

All parties are in agreement that an international pharmaceutical excipient good manufacturing practice (GMP) and good distribution practice (GDP) certification scheme will ensure the safety of these key ingredients of drug products throughout the supply chain, especially where certification is based on the IPEC-PQG GMP and the IPEC GDP Guides for pharmaceutical excipients.

The EXCiPACT™ scheme proposes independent certification of manufacturers and suppliers of excipients. This is a means of ensuring patient safety and improving assurance of supplier quality, while minimizing overall supply chain costs. In developing this scheme the following framework has been used:

**Key principles:**

- “International”: an excipient manufacturer’s certification should have the same acceptance and value anywhere in the world
- “Inclusivity”: The scheme should provide quality standards and be applicable to as many excipients as possible
- “Accessibility”: The scheme should be accessible to as many 3rd party organizations as possible

---

\(^1\) Food Drug &Cosmetic Act Section 201(g)(1) define components of drugs as drugs which therefore requires GMP as defined in Section 501 (a)(2)(B) and a drug whose name appears in an official compendium must meet the standards set forth in the official compendium [section 501(b)]
Excipient GMP and GDP Certification Scheme

- “Evolution not revolution”: Existing best practices, guides and standards should be utilised and adapted wherever possible
- “Simplicity”: The overall scheme should be as simple as possible

Key deliverables:
- GMP and GDP standards suitable for 3rd party auditing
- Definition of auditor competency for the delivery of the scheme
- Certification scheme rules for 3rd party audit organizations
- Publication, communication and on-going maintenance of the schemes, standards and guidelines developed.

Acknowledgements
EXCiPACT™ is the result of a huge amount of effort and commitment from a large team of people spanning two continents and many countries. These individuals are members of the partner organizations that comprise EXCiPACT™ without whom these standards and requirements could not have been prepared.

European Fine Chemicals Group (EFCG)
The European Fine Chemicals Group - a sector group of CEFIC, the European Chemicals Industry Council - was formed in 2004 to be the forum, the focus and the voice for European Fine Chemical Manufacturers. The issues affecting its members’ competitiveness drive the EFCG agenda. One such issue is the need for certifiable, enforceable, adequate and appropriate quality standards for pharmaceutical excipients destined for use in medicines worldwide.

For further information visit http://www.efcg.cefic.org

Federation of European Chemical Distributors (FECC)
The European Association of Chemical Distributors (FECC) is the European voice of the chemical distribution industry. With a growing membership of companies and national associations, FECC represents over 1200 entities many of which are small and medium sized enterprises. Members service a very wide range of industries and meet the manufacturing requirements of sectors as diverse as electronics, paints and textiles to cosmetics, food, feed and pharmaceuticals, each with their own diverse demands and purchase volumes.

For further information visit www.fecc.org

International Pharmaceutical Excipients Council (IPEC Federation)
IPEC is an international industry association formed in 1991 by manufacturers and end-users of excipients. It is an association comprising three regional pharmaceutical excipient industry associations covering the United States, Europe, China and Japan (which are known respectively as IPEC-Americas, IPEC Europe, IPEC China and IPEC Japan). IPEC’s objective is to contribute to the development and harmonisation of international excipient standards, the introduction of useful new excipients.
to the marketplace and the development of good manufacturing and distribution practice for excipients.

IPEC first published its GMP Guide for Bulk Pharmaceutical Excipients in 1995 and it was revised in 2001 to align it with ISO 9001:2000 and again in 2006 to bring it fully up to date. This document has also been adopted by the USP and has been published as general chapter <1078> with only minor editorial changes to make it suitable for that publication. Collaboration with PQG led to the established and widely accepted IPEC/PQG Good Manufacturing Practices Guide for Pharmaceutical Excipients, 2006.


For further information visit www.ipec.org

**Pharmaceutical Quality Group (PQG)**

The PQG was formed in 1977 to promote development of a consistent approach to pharmaceutical quality and good manufacturing practice. The group has since expanded, and in 1990 the PQG published three codes of practice to cover pharmaceutical raw materials, printed and contact packaging materials. In 1995 the codes were revised and were integrated with ISO 9002:1994. The code for raw materials was revised and reissued as PS 9100:2002 Pharmaceutical excipients, an application standard and GMP guide for pharmaceutical excipients. Collaboration with PQG led to the established and widely accepted IPEC/PQG Good Manufacturing Practices Guide for Pharmaceutical Excipients, 2006.

For further information visit www.pqg.org
## Individual Acknowledgements

IPEC Europe, IPEC-Americas, FECC, EFCG and PQG greatly appreciate and acknowledge the many hours of hard work the following individuals devoted during the past 3 years to creating these Standards and the generous support provided by their employers.

### Global Steering Committee

The role of chair rotated every 6 months.

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrian Bone</td>
<td>Eli Lilly</td>
<td>IPEC Europe</td>
</tr>
<tr>
<td>Alexandra Brand, PhD</td>
<td>BASF SE</td>
<td>EFCG Chair</td>
</tr>
<tr>
<td>Arnulf Heubner, PhD (deceased)</td>
<td>Merck KGaA</td>
<td>EFCG</td>
</tr>
<tr>
<td>Art Falk</td>
<td></td>
<td>IPEC Americas</td>
</tr>
<tr>
<td>Beam Suffolk</td>
<td>Dow</td>
<td>IPEC Europe</td>
</tr>
<tr>
<td>Dale Carter, MS, CQA</td>
<td>Huber</td>
<td>IPEC Americas  Chair</td>
</tr>
<tr>
<td>David B. Klug, MS</td>
<td>Sanofi U.S.</td>
<td>IPEC Americas</td>
</tr>
<tr>
<td>David Schoneker, MS</td>
<td>Colorcon, Inc.</td>
<td>IPEC Americas</td>
</tr>
<tr>
<td>Folker Ruchatz, PhD</td>
<td>BASF SE</td>
<td>EFCG Chair</td>
</tr>
<tr>
<td>Hubertus Folttmann, PhD</td>
<td>BASF SE</td>
<td>IPEC Europe</td>
</tr>
<tr>
<td>Iain Moore, PhD</td>
<td>Croda Europe Ltd</td>
<td>IPEC Europe</td>
</tr>
<tr>
<td>Janeen Skutnik</td>
<td>Pfizer</td>
<td>IPEC Americas  Chair</td>
</tr>
<tr>
<td>Joel D'Silva</td>
<td>FECC</td>
<td>FECC</td>
</tr>
<tr>
<td>Kevin McGlue C Sci, CChem, MRSC</td>
<td>Colorcon</td>
<td>IPEC Europe</td>
</tr>
<tr>
<td>Mark McCart</td>
<td>Ashland (formerly ISP Europe)</td>
<td>EFCG</td>
</tr>
<tr>
<td>Monika Drazek</td>
<td>FECC</td>
<td>FECC</td>
</tr>
<tr>
<td>Najib Sehat, PhD</td>
<td>Merck KGaA</td>
<td>EFCG</td>
</tr>
<tr>
<td>Norman Randall, PhD</td>
<td>Norman Randall Consulting Ltd</td>
<td>PQG</td>
</tr>
<tr>
<td>Patricia Rafidison</td>
<td>Dow Corning</td>
<td>IPEC Europe    Chair</td>
</tr>
<tr>
<td>Steve Moss, PhD</td>
<td>GlaxoSmithKline</td>
<td>PQG</td>
</tr>
<tr>
<td>Tim Boelke</td>
<td>BASF SE</td>
<td>EFCG</td>
</tr>
<tr>
<td>Tony Scott</td>
<td>Tony Scott Associates</td>
<td>EFCG Chair</td>
</tr>
</tbody>
</table>
# Auditor Competency Team

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Organization</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashley McCraight, MChemA, FRSC</td>
<td>Consultant</td>
<td>PQG</td>
<td>Chair</td>
</tr>
<tr>
<td>Frank Milek, PhD</td>
<td>Aug. Hedinger GmbH &amp; Co. KG</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Iain Moore, PhD</td>
<td>Croda Europe Ltd</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Ian Birch, BSc (Hons)</td>
<td>Arrow Generics Ltd (part of the Watson group)</td>
<td>PQG</td>
<td></td>
</tr>
<tr>
<td>Irwin Silverstein, PhD</td>
<td>IPEA</td>
<td>IPEC Americas</td>
<td></td>
</tr>
<tr>
<td>Jayne Nicholas, MRSC</td>
<td>Bristol-Myers Squibb</td>
<td>PQG</td>
<td></td>
</tr>
</tbody>
</table>

# Communications Team

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Organization</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beam Suffolk</td>
<td>Dow</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Christophe Guechot</td>
<td>Solvay</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Frithjof Holtz</td>
<td>Merck KGaA</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Hubertus Folttmann, PhD</td>
<td>BASF SE</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Ian McKeown, PhD</td>
<td>PQ Silicas UK Ltd</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Joel D'Silva</td>
<td></td>
<td>FECC</td>
<td></td>
</tr>
<tr>
<td>Mark McCart</td>
<td>Ashland (formerly ISP Europe)</td>
<td>EFCG</td>
<td></td>
</tr>
<tr>
<td>Monika Drazek</td>
<td></td>
<td>FECC</td>
<td>Chair</td>
</tr>
<tr>
<td>Norman Randall, PhD</td>
<td>Norman Randall Consulting Ltd</td>
<td>PQG</td>
<td></td>
</tr>
<tr>
<td>Patricia Rafidison</td>
<td>Dow Corning</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Steffen Denzinger, PhD</td>
<td>Merck KGaA</td>
<td>EFCG</td>
<td></td>
</tr>
<tr>
<td>Tony Scott</td>
<td>Tony Scott Associates</td>
<td>EFCG</td>
<td>Chair</td>
</tr>
</tbody>
</table>

# GMP Annex Team

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Organization</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alberto Galasco</td>
<td>Solvay</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Armand M. Janssen</td>
<td>DFE Pharma</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Christophe Guechot</td>
<td>Solvay</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Eisele, Johanna, PhD</td>
<td>Evonik Industries</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Felicitas Guth</td>
<td>BASF SE</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Flavia Acre</td>
<td>Eli Lilly</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Frithjof Holtz</td>
<td>Merck KGaA</td>
<td>IPEC Europe</td>
<td>Chair</td>
</tr>
<tr>
<td>Gianluca Minestrini</td>
<td>Roche</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Organization</td>
<td>Region</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>Iain Moore, PhD</td>
<td>Croda Europe Ltd</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Ian McKeown, PhD</td>
<td>PQ Silicas UK Ltd</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Irwin Silverstein, PhD</td>
<td>IPEA</td>
<td>IPEC Americas</td>
<td></td>
</tr>
<tr>
<td>Jeff Brambora</td>
<td></td>
<td>IPEC Americas</td>
<td></td>
</tr>
<tr>
<td>Jesus Rivas</td>
<td>Eli Lilly</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Karen Hudson</td>
<td>Eli Lilly</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Kevin McGlue CSci, CChem, MRSC</td>
<td>Colorcon</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Rainer Fendt</td>
<td>BASF SE</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Rene Leubert</td>
<td>Evonik Industries</td>
<td>IPEC Europe</td>
<td></td>
</tr>
<tr>
<td>Steve Moss, PhD</td>
<td>GlaxoSmithKline</td>
<td>PQG Chair</td>
<td></td>
</tr>
<tr>
<td>Dale Carter, MS, CQA</td>
<td>Huber</td>
<td>IPEC Americas</td>
<td></td>
</tr>
<tr>
<td>Art Falk</td>
<td></td>
<td>IPEC Americas</td>
<td></td>
</tr>
<tr>
<td>David Klug, MS</td>
<td>Sanofi U.S.</td>
<td>IPEC-Americas</td>
<td></td>
</tr>
</tbody>
</table>

**3rd Party Audit Organization Requirements Team**

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
<th>Region</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allan Whiston, CQP FCQI C Eng MI MechE</td>
<td>QA Resolutions Ltd</td>
<td>IPEC Europe</td>
</tr>
<tr>
<td>Dale Carter, MS, CQA</td>
<td>Huber</td>
<td>IPEC Americas</td>
</tr>
<tr>
<td>Ian McKeown, PhD</td>
<td>PQ Silicas UK Ltd</td>
<td>IPEC Europe</td>
</tr>
<tr>
<td>Kevin McGlue Csci, Cchem, MRSC</td>
<td>Colorcon</td>
<td>IPEC Europe</td>
</tr>
<tr>
<td>Norman Randall, PhD</td>
<td>Norman Randall Consulting Ltd</td>
<td>PQG Chair</td>
</tr>
</tbody>
</table>

**GDP Annex Team**

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
<th>Region</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allan Whiston, CQP, FCQI, CEng, MI MechE</td>
<td>QA Resolutions Ltd</td>
<td>IPEC Europe</td>
</tr>
<tr>
<td>Andreas Lekebusch</td>
<td>Biesterfeld Spezialchemie GmbH</td>
<td>IPEC Europe</td>
</tr>
<tr>
<td>Christiane Dzala</td>
<td>Bayer</td>
<td>IPEC Europe</td>
</tr>
<tr>
<td>Dale Carter, MS, CQA</td>
<td>Huber</td>
<td>IPEC Americas</td>
</tr>
<tr>
<td>Fank Milek, PhD</td>
<td>Aug. Hedinger GmbH &amp; Co. KG</td>
<td>IPEC Europe  Chair</td>
</tr>
<tr>
<td>Axel Sewin, PhD</td>
<td>VWR International AG</td>
<td>IPEC Europe</td>
</tr>
<tr>
<td>Mathias Brenken, PhD Anlagengesellschaft mbH</td>
<td>Dow Deutschland</td>
<td>IPEC Europe</td>
</tr>
<tr>
<td>Name</td>
<td>Company/Position</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Ian McKeown, PhD</td>
<td>PQ Silicas UK Ltd</td>
<td></td>
</tr>
<tr>
<td>Irwin Silverstein, PhD</td>
<td>IPEA</td>
<td></td>
</tr>
<tr>
<td>Steven Hewitt, PhD</td>
<td>Sanofi</td>
<td></td>
</tr>
</tbody>
</table>

**EXCiPACT™ Certification Scheme**

<table>
<thead>
<tr>
<th>Name</th>
<th>Company/Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allan Whiston, CQP FCQI C Eng MiMechE</td>
<td>QA Resolutions Ltd IPEC Europe</td>
</tr>
<tr>
<td>Dale Carter, MS, CQA</td>
<td>Huber</td>
</tr>
<tr>
<td>Iain Moore, PhD</td>
<td>Croda Europe Ltd</td>
</tr>
<tr>
<td>Ian McKeown, PhD</td>
<td>PQ Silicas UK Ltd</td>
</tr>
<tr>
<td>Irwin Silverstein, PhD</td>
<td>IPEA</td>
</tr>
<tr>
<td>Janeen Skutnik</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Lore Vignoli</td>
<td>Roquette Frères</td>
</tr>
<tr>
<td>Norman Randall, PhD</td>
<td>Norman Randall Consulting Ltd PQG</td>
</tr>
</tbody>
</table>

**Business Plan Team**

<table>
<thead>
<tr>
<th>Name</th>
<th>Company/Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dale Carter, MS, CQA</td>
<td>Huber</td>
</tr>
<tr>
<td>Folker Ruchatz, PhD</td>
<td>BASF SE</td>
</tr>
<tr>
<td>Frithjof Holtz</td>
<td>Merck KGaA</td>
</tr>
<tr>
<td>Hubertus Folttmann, PhD</td>
<td>BASF SE</td>
</tr>
<tr>
<td>Iain Moore, PhD</td>
<td>Croda Europe Ltd</td>
</tr>
<tr>
<td>Mark McCart</td>
<td>Ashland (formerly ISP Europe) EFCG</td>
</tr>
<tr>
<td>Najib Sehat, PhD</td>
<td>Merck KGaA</td>
</tr>
<tr>
<td>Tony Scott</td>
<td>Tony Scott Associates EFCG</td>
</tr>
</tbody>
</table>

**Review and Proofing Team**

<table>
<thead>
<tr>
<th>Name</th>
<th>Company/Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrian Bone</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td>Iain Moore, PhD</td>
<td>Croda Europe Ltd</td>
</tr>
<tr>
<td>Ian McKeown, PhD</td>
<td>PQ Silicas UK Ltd</td>
</tr>
<tr>
<td>Lore Vignoli</td>
<td>Roquette Frères</td>
</tr>
<tr>
<td>Steve Moss, PhD</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Tony Scott</td>
<td>Tony Scott Associates EFCG</td>
</tr>
</tbody>
</table>
### Executive / Operations Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dale Carter, MS, CQA</td>
<td>Huber</td>
<td>IPEC Americas</td>
</tr>
<tr>
<td>Folker Ruchatz, PhD</td>
<td>BASF SE</td>
<td>EFCG</td>
</tr>
<tr>
<td>Hubertus Folttmann, PhD</td>
<td>BASF SE</td>
<td>IPEC Europe</td>
</tr>
<tr>
<td>Iain Moore, PhD</td>
<td>Croda Europe Ltd</td>
<td>IPEC Europe</td>
</tr>
</tbody>
</table>

These standards would not have been completed without the contributions from many others who posted review comments, and engaged in discussions about the content. We thank them all.

Thanks also to Carole Capitaine based in the IPEC Federation secretariat for all her support, and to all the unnamed contributors who have commented, reviewed and participated in the preparation of these standards.
Excipient GMP and GDP Certification Scheme

General Introduction
If the appropriate quality standards are not followed, excipients may pose a hazard to the end patient safety. Thus, the requirement to have a robust quality system in place that assures the quality and purity of excipients remains an imperative, particularly as events with fraudulent claims of pharmaceutical raw material purity have resulted in so many tragedies.

These tragedies have taught us that it is not sufficient to only apply the principles of Good Manufacturing Practice (GMP) to the manufacture of the excipient but also that Good Distribution Practice Principles (GDP) must be applied to the excipient distribution. Excipient quality can be better assured if all steps in the supply chain, from manufacturer through to user, adopt suitable standards that are capable of independent verification – i.e. Good Distribution Practices (GDP). Patients can be as much at risk from failures in the supply chain as from failures in manufacture.

Legislators and regulatory authorities in both Europe and the USA continue to address the weaknesses in the application of GMP and GDP to pharmaceutical excipients so as to minimise patient risk. The USA FDA has clearly stated its expectation that each drug product manufacturer has physically audited every API and excipient supplier they use. There are also developments in Europe where similar requirements are proposed. Such requirements and expectations pose a burden in terms of cost and time for excipient users and their suppliers alike. Some excipient supplier sites could be asked to host hundreds of audits as a result of these initiatives. In recognition of these issues the authorities have clearly stated that the drug product manufacturer can utilise 3rd party audit organizations to perform the audits. Thus a 3rd party audit organization could perform the audit reducing the burden in time and resources for both excipient user and excipient supplier. However, for such 3rd party audit organizations to be accepted within the industry both the standard used to assess excipient suppliers and the competency of their auditors has to be addressed.

Many excipient suppliers are already registered to the Quality Management System standard, ISO 9001:2008 and this provides an excellent framework on which to build and develop systems suitable for the manufacture and supply of pharmaceutical excipients. This is the basis for these EXCiPACT™ standards; two annexes to ISO 9001:2008 which cover GMP and GDP requirements. Thus excipient manufacturers would be assessed to ISO 9001:2008 and the EXCiPACT™ GMP annex together, whereas distributors would utilise ISO 9001:2008 and the EXCiPACT™ GDP Annex. Of course, if an excipient supplier conducted both manufacturing and distribution activities then they could be assessed to both the GMP and GDP Annexes. Those suppliers which do not hold ISO 9001:2008 certification will find the

---

2  http://blog.pharmtech.com/2010/05/05/are-photo-libraries-the-next-supply-chain-savior-fda-comments-at-excipientfest/
forthcoming US National Standard (Good Manufacturing Standards (GMP) for Pharmaceutical Excipients) an alternative approach: this standard is also based on the IPEC-PQG GMP Guide and has been synchronised with the EXCiPACT™ GMP and GDP standards during its development.

The remaining sections of EXCiPACT™ cover the requirements for 3rd party audit organizations, firstly for auditor competency and secondly for quality system requirements for these organizations. The former is based on ISO 19011:2002, Guidelines for Quality and/or Environmental Management System Auditing, whereas the latter is based on ISO /IEC17021:2006, Conformity assessment -- Requirements for Bodies Providing Audit and Certification of Management Systems.

Together these standards will ensure pharmaceutical excipient suppliers implement best practices to assure excipient quality and safety and that EXCiPACT™ approved 3rd party audit organizations can provide a credible service to the pharmaceutical industry and its regulatory authorities.

This international pharmaceutical excipient GMP and GDP certification scheme will provide manufacturers, suppliers and users of excipients with additional confidence that suppliers of these critical components of drug products are safe to use.
Requirements for GMP for Pharmaceutical Excipients: Foreword

Many excipient manufacturers and distributors are already registered to ISO 9001:2008, “Quality Management Systems – Requirements”, and as a consequence EXCiPACT™ has developed this annex to that standard to allow such organizations to be assessed simultaneously to ISO 9001:2008 and to the requirements for GMP for pharmaceutical excipients. This annex to ISO 9001:2008 is based on the Joint IPEC-PQG Good Manufacturing Practices Guide for Pharmaceutical Excipients 2006. The guidance (“how to do”) in that document has been converted to an auditable standard (“what to do”) and then the parts already covered by ISO 9001:2008 removed resulting in this annex.

Organizations that manufacture and distribute excipients can opt to be certified to this annex and the corresponding GDP Annex together or separately depending on their business arrangements.

The main text that follows is based on the headings in ISO 9001:2008 and the details are the GMP requirements:

Texts in Bold are ISO 9001:2008 Headings
Standard Texts are GMP requirements

*Italicised texts are taken directly from ISO 9001:2008 to provide context to the Annex statements which they immediately follow.*

For full comprehension this annex should be read in conjunction with ISO 9001:2008 which can be purchased via www.iso.org
0  Introduction
This document is an annex to ISO 9001:2008. Organizations requiring certification to this Annex shall hold an ISO 9001:2008 certificate issued under accreditation of an International Accreditation Forum member National Accreditation Body and covering the scope of manufacture and or distribution of relevant excipient products. For organizations not holding a current ISO 9001:2008 certificate and for recertification, assessment against the requirements of this Annex and ISO 9001:2008 may be conducted simultaneously.

Note  increasingly users of pharmaceutical excipients are required by regulatory authorities to include audits of their suppliers in their supplier qualification process. The objective of these standards is to reduce the number of these audits. EXCiPACT™ certification may not always be suitable for every customer’s supplier qualification requirements, so audits at suppliers of excipients critical to the users’ application may still be necessary.

0.1  General
Excipient manufacture shall be carried out in accordance with the Good Manufacturing Practice (GMP) principles consistent with this Annex. The objective of excipient GMP is to ensure that the manufacture of excipients results in a consistent material with the desired appropriate quality characteristics, to assure product integrity and consistent quality, to avoid product contamination, and to ensure that appropriate records are maintained.

Throughout this document, references to “GMP for pharmaceutical excipients” will be referred to as “GMP” and “excipients” to mean “pharmaceutical excipients”.

An excipient can only be assigned as pharmaceutical grade when it is in compliance with a pharmacopoeial specification (if existing for the specific excipient) and/or appropriate regulatory requirements and is manufactured, repackaged, and handled in accordance with excipient GMPs (e.g. EXCiPACT™, IPEC-PQG Excipient GMP, USP <1078>).

This document includes additional requirements that support the application of GMP to the manufacture of excipients. The section headings are consistent with those in ISO 9001:2008. Where a list does not start with “a)” then it is an addition to the text of the corresponding paragraph and preceding bullets in ISO 9001:2008, e.g. in 6.2.2, where the list starts with” f)”. Where reference is made to ISO 9001 this means ISO 9001:2008.

0.2  Process approach
No additional requirements to ISO 9001.

0.3  Relationship with ISO 9004
No additional requirements to ISO 9001.

0.4  Compatibility with other management systems
No additional requirements to ISO 9001.
1 Scope

1.1 General
In this Annex the term “if/as applicable” is used several times, when a requirement is qualified by this phrase, it is deemed to be “applicable” unless the organization has a documented risk assessment which concludes that it is not applicable. This risk assessment shall also include operations covered in this Annex which are not carried out by the organization (outsourced).

Purpose and Scope
The scope of this Annex is to act as an addition to ISO 9001 setting out the minimum GMP requirements for excipients. These principles are to be applied from the point in the manufacturing process where GMP has been determined to begin (see 4.2.2 e).

Note the requirements of this Annex are not sufficient for the manufacture of sterile excipients as additional controls will be required.

The Annex and its Use

1.2 Application
This Annex includes requirements additional to those for ISO 9001 certification purposes and enables organizations to demonstrate conformity with GMP for the manufacture of excipients.

2 Normative references

3 Terms and Definitions
See section Definitions and References.

Pharmaceutical excipients
Pharmaceutical excipients are substances other than the Active Pharmaceutical Ingredient that have been appropriately evaluated for safety and are intentionally included in a drug delivery system.

4 Quality Management System
4.1 General requirements
Where manufacturing, testing or other operations that could affect excipient quality are outsourced the organization shall:

a) Define the responsibility for quality and the control measures within the quality management system (see also 7.4),

b) Demonstrate that the applicable GMP principles in accordance with this Annex are applied to those operations.
Note: quality risk management can be useful for identifying and prioritising areas for continual improvement.

4.2 Documentation requirements

4.2.1 General
The design, organization and documentation of the quality system shall be structured to facilitate common understanding and consistent application.

The quality management system documentation shall include:

- e) the organization’s overall intentions and approach to GMP
- f) documented procedures required for conformance to this Annex
- g) a documented risk assessment that defines and justifies when the “as applicable” clauses in this Annex are not implemented.

4.2.2 Quality manual
The organization shall establish and maintain a quality manual that includes or references:

- d) a definition of the extent to which this Annex applies to its quality management system and its business processes,
- e) identification and justification of the point at which the full requirements of this Annex applies to each manufacturing process.

Note: the GMP principles in this annex may be applied earlier than this point in the excipient manufacturing processes.

4.2.3 Control of documents
Documents that impact product quality shall have a defined owner. The Quality Unit shall review and approve documents that impact product quality, including changes to these documents.

Note: the Quality Unit may delegate this activity, unless otherwise noted herein, if appropriate controls are in place and are documented (see 5.5.1).

Electronic documentation shall meet the requirements stated above.

If electronic signatures are used on documents they shall be controlled to be as secure as a hand written signature.

Note: electronic documents and signatures may also need to satisfy local regulatory requirements.

4.2.4 Control of records
The organization shall define which records, results and reports of subcontractor activities shall be retained and by whom.

Electronic records shall be subject to the same controls as those required for other records.

Entries in quality records shall be clear, indelible and made directly after performing the activity (in the order performed), signed or initialled and dated by the person making the entry. Corrections to entries shall be signed or initialled and dated, leaving the original entry legible.
The record retention period shall not be less than one year past the excipient’s expiry or first re-evaluation date. If the manufacturer does not stipulate an expiry or revaluation date, the record retention period shall be five years from the date of manufacture.

Certificates of Analysis (COAs) and Certificates of Conformity (COCs) are records that are required to ensure product traceability back to the manufacturer. Documented procedures shall be implemented to ensure control of COAs.

4.3 Change Control

There shall be a documented procedure defining the responsibilities and requirements for the evaluation and approval of changes that may impact the quality of the excipient including the impact on any regulatory submissions made by the excipient supplier. Evaluation and approval of changes shall occur prior to the implementation. The quality unit shall approve significant changes that may impact on the quality of the excipient. Where the impact on the quality of the excipient is determined to be significant, such changes shall be communicated to customers and, as applicable, regulatory authorities (see 7.2.3). Records of the change control process shall be retained.

The impact of changes on validated processes and activities shall be assessed (see 7.5.2).

Note 1: for Guidance refer to the International Pharmaceutical Council of the Americas Significant Change Guide for Bulk Pharmaceutical Excipients 2009:

Note 2: Quality risk management can be utilized to evaluate proposed changes. The level of effort and formality of the evaluation should be commensurate with the level of risk.

5 Management responsibility

5.1 Management commitment

Top management shall provide evidence of its commitment to the development and implementation of the quality management system and continually improving its effectiveness by:

f) ensuring that GMP objectives are established,

g) communicating to the organization the importance of conforming to the requirements of this Annex.

5.2 Customer focus

Top management shall ensure that customer requirements related to GMP for pharmaceutical excipients are determined, agreed with the customer and met.

5.3 Quality policy

Top management shall ensure that the quality policy:

f) includes a commitment to comply with GMP requirements.
5.4 Planning

5.4.1 Quality objectives
Top management shall set objectives for adherence to the requirements of this Annex.

5.4.2 Quality Management system planning
No additional requirements to ISO 9001.

5.5 Responsibility, authority and communication

5.5.1 Responsibility and authority
A Quality Unit independent from production shall be responsible at a minimum for:

- ensuring quality critical activities are identified and undertaken as defined,
- approving suppliers of quality critical materials and services,
- approving or rejecting raw materials, packaging components, intermediates and finished excipients,
- reviewing batch records to ensure that significant deviations have been fully investigated and documented,
- ensuring corrective and preventive actions are implemented,
- approving significant changes to quality critical equipment, processes, specifications, procedures, and test methods (see 4.3),
- approving the results of investigations into deviations from process instructions, test or measurement failures, and complaints,
- approving or rejecting the excipient if it is manufactured, processed, packaged, or held under contract by another company,
- developing and implementing an internal audit program,
- ensuring that providers of outsourced services have agreed to comply with the relevant sections of this Annex.

The Quality Unit may delegate some of these activities if appropriate controls are in place and are documented.

The independence of the Quality Unit shall be documented and demonstrated by showing the inter-departmental relationships as well as relationship to top management.

5.5.2 Management representative
Top management shall appoint a member of the organization’s management who, irrespective of other responsibilities, shall have the responsibility and authority that includes:

d) ensuring the promotion and awareness of regulatory requirements throughout the organization.

5.5.3 Internal communication
GMP and regulatory requirements shall be communicated as applicable throughout the organization.
Top management shall be promptly notified about any quality critical situations in accordance with a documented procedure (for example those that would lead to a product recall from the market).

5.6 Management review

5.6.1 General

Note: necessary changes identified in the management reviews should be assessed and implemented via the change control procedure (4.3).

5.6.2 Review input

Input into the management review shall include information on

h) new, revised or proposed regulatory requirements.

5.6.3 Review output

The output from the management review shall include any decisions and actions related to

d) improvements necessary as a result of the review of regulatory requirements.

6 Resource management

6.1 Provision of resources

The organization shall determine and provide the resources needed:

c) to meet the GMP requirements in this Annex which have been determined to be applicable.

6.2 Human resources

6.2.1 General

Personnel whose role has an impact on excipient quality shall have written job descriptions.

Consultants advising on the design, production, packaging, testing or storage of excipients shall have sufficient education, training and experience or any combination thereof to advise on the subject for which they are retained. Records shall be maintained listing the name, address and qualifications of consultants providing advice concerning any aspect of the Quality Management System and the type of service they provide.

6.2.2 Competence, training and awareness

The organization shall:

f) ensure training, including the requirements of this Annex as it relates to the employee’s function, is conducted by qualified individuals,

g) ensure training is conducted prior to carrying out the assigned duties,

h) ensure training includes

i. GMP principles and the contents of this Annex,

ii. the risk of contamination to excipient quality,

iii. the potential hazard to end user/patient if an excipient is contaminated,
Requirements for GMP for Pharmaceutical Excipients

iv. potential impact on product quality and use due to departures from specified procedures,
v. the risk of excipient contamination from deficiencies in personal hygiene,
vi. the reporting of significant failures and deviations from procedures,

i) ensure GMP refresher training is conducted with sufficient frequency to ensure that employees remain familiar with applicable elements of this Annex.

6.2.3 Personnel Hygiene
To protect excipients from contamination, the organization shall conduct a risk assessment to identify areas in which the excipient is at risk of contamination from personnel or their activities. The following shall be considered at a minimum to prevent excipient contamination:

a) the personnel themselves and their attire, including personal protective equipment,
b) loose items, including those in pockets,
c) unauthorized access to designated areas (see 6.3),
d) the potential impact of any person with an apparent illness or open lesions,
e) the storage and use of food, drink, personal medication, tobacco products or similar items.

Where existing controls to minimize the risks of excipient contamination are not considered effective then additional measures shall be documented and implemented.

6.3 Infrastructure
The infrastructure shall be designed, operated, cleaned and maintained to avoid contamination and mix-ups of raw materials, intermediates and the excipient.

The organization shall conduct a risk assessment based on the organization’s intended use of the infrastructure to identify areas in which the excipient is at risk for contamination from deficiencies in buildings and/or facilities. The risk assessment shall consider the following at a minimum to identify where the excipient is at risk from contamination:

a) location of the operations (e.g. internal, external),
b) state of repair of the building and facility,
c) suitable size, construction and location,
d) ability to maintain a suitably clean building and facility environment,
e) operations that can affect the excipient quality,
f) presence of airborne contaminants, especially highly sensitizing or toxic substances.

Where existing controls to minimize the risks of excipient contamination are not considered effective then additional measures shall be documented and implemented.
There shall be controls to ensure that defective equipment shall not be used. Equipment which may impact excipient quality shall be commissioned before initial use to ensure that it is functioning as intended.

Equipment shall be placed and constructed to facilitate cleaning and maintenance. The use, cleaning and maintenance of quality critical equipment shall be recorded. The status of equipment shall be readily identifiable. Equipment shall be constructed so that contact surfaces will not be reactive, additive, or absorptive.

Production processes associated with highly sensitizing or toxic materials shall be separated from those used for excipients, unless measures to prevent cross-contamination have been implemented and the effectiveness of these measures have been demonstrated.

The organization shall conduct a risk assessment considering the risk to excipient quality from utilities and process materials (e.g. nitrogen, compressed air, steam, lubricants etc.) used in the production, storage or transfer of materials. Suitable control measures shall be implemented to mitigate the identified risks.

Computerized systems that may impact upon excipient quality shall have documented controls for operation, maintenance, back-up or archiving, disaster recovery and include measures to prevent unauthorized access or changes to software, hardware or data. Changes to computerized systems that may impact upon excipient quality shall be verified and documented (see Section 4.3).

Water, where used in contact with excipients shall conform to written specifications and be monitored to be of a suitable quality for its intended use. Unless otherwise justified, water shall, at a minimum meet WHO guidelines for drinking (potable) water quality.

If interruptions in supply or deviations in the quality of such water occur, evidence and appropriate rationale shall be documented to show such interruptions have not compromised the quality of the excipient.

Product contact water shall be produced and distributed in such a manner so as to prevent contamination entering or backflows in the system.

Access to areas of the buildings and facilities designated as limited access areas shall be controlled.

6.4 Work environment
The work environment shall be managed and controlled to minimize risks of excipient contamination. A documented risk assessment shall be carried out to determine the necessary controls.

The documented risk assessment shall consider the following controls, as applicable:

a) air handling systems,
b) special environments,
c) cleanliness and sanitary conditions,
d) waste segregation and disposal,
e) pest control,

f) other risk assessments required by this Annex.

Where maintenance of the work environment is critical to excipient quality, the controls shall be documented.

6.4.1 Air Handling
Where the risk assessment has identified the need for an air handling system, it shall be designed and maintained to assure adequate protection of the excipient. The effectiveness shall be demonstrated.

6.4.2 Controlled Environment
Where the risk assessment has identified the need for a controlled environment, it shall be monitored to assure product quality. Where an inert atmosphere is required, the gas shall be treated as a quality critical raw material (see 7.4.3) or intermediate.

If interruptions in the controlled environment occur, the organization shall perform an investigation. Evidence and appropriate rationale shall be documented to show that such interruptions have not compromised the quality of the excipient.

6.4.3 Cleaning and Sanitary Conditions
Where the risk assessment (see 6.4) has identified the need for clean and sanitary conditions, the organization shall document procedures assigning responsibility for cleaning and sanitation. Cleaning records shall be maintained. Waste shall be segregated and disposed of in a timely and appropriate manner. If waste is not disposed of immediately, it shall be suitably identified.

6.4.4 Pest Control
Where the risk assessment (see 6.4) has identified the need for pest control, the organization shall document the pest control program.

6.4.5 Lighting
Adequate lighting shall be provided to facilitate cleaning, maintenance and operations. Where the excipient is exposed to the work environment or stored, lighting shall be shatter-proof or otherwise protected.

6.4.6 Drainage
In areas where the excipient is exposed to the work environment or stored, drains shall be of adequate size. Drains connected directly to a sewer shall be provided with an air break or other mechanical device to prevent back-siphoning.

6.4.7 Washing and Toilet Facilities
Personnel washing facilities shall be provided, which ensure suitable hygiene standards can be maintained. Clean toilet facilities shall be separate from but easily accessible to working areas. Facilities for showering and/or changing clothes shall be provided, where identified in the personnel hygiene risk assessment (see 6.2.3).
7 Product realization

7.1 Planning of product realization

In planning product realization, the organization shall determine the following, as appropriate:

e) documented testing programs for quality critical materials, intermediates and excipients that include appropriate specifications, sampling plans, test and release procedures,

f) environmental and hygiene control programs to minimize risks of contamination of the excipient,

g) documented procedures describing activities relating to the storage and distribution of excipients,

h) implementation of identified actions from risk assessments described in other sections of this Annex.

The use of recycled or recovered materials containing recoverable amounts of excipient, reactants or intermediates shall be justified.

7.2 Customer-related processes

7.2.1 Determination of requirements related to the product

Statutory and regulatory requirements related to the product shall include as a minimum:

• Compendial general requirements, including TSE/BSE,
• Residual Solvents,
• Elemental impurities.

Changes requiring notification and/or documented prior approval from the customer shall be determined.

7.2.2 Review of requirements related to the product

No additional requirements to ISO 9001.

7.2.3 Customer communication

The organization shall determine and implement effective arrangements for communicating with customers in relation to:

d) significant changes. (See also 4.3 and 7.2.1),

e) critical deviations which become known after delivery of the excipient (see 7.2.1 and 7.2.2),

f) product recall.

Certificates of Analysis, which are traceable to the original manufacturers COA, shall be provided for each batch shipped.

Where the excipient is not manufactured by the supplier, the original manufacturer’s identity and production site shall be communicated to the customer.

If production of the excipient is outsourced then this shall be communicated to the customer.
7.3 Design and development
The extent of conformance to this Annex for development batches of excipients shall be communicated to the customer (see section 7.2.1).

7.3.1 Design and development planning
No additional requirements to ISO 9001.

7.3.2 Design and development inputs
No additional requirements to ISO 9001.

7.3.3 Design and development outputs
No additional requirements to ISO 9001.

7.3.4 Design and development review
No additional requirements to ISO 9001.

7.3.5 Design and development verification
No additional requirements to ISO 9001.

7.3.6 Design and development validation
No additional requirements to ISO 9001.

7.3.7 Control of design and development changes
No additional requirements to ISO 9001.

7.4 Purchasing

7.4.1 Purchasing process
Quality critical materials and services shall be identified and justified.

**Note:** risk assessment techniques are a useful way of identifying quality critical materials and services.

Suppliers of quality critical materials and services shall be approved by the Quality Unit after a documented evaluation of the supplier’s quality management system, including adequate evidence that they can consistently meet agreed requirements.

The organization shall require that contract manufacturers or laboratories adhere to the relevant sections of this Annex (See 4.1).

Primary packaging material specifications shall be established and a written procedure shall clearly define primary packaging materials for each individual excipient based upon the excipient’s properties and stability.

7.4.2 Purchasing information
The organization shall require that it is notified by its suppliers of subcontracting or other significant changes to materials that may potentially impact excipient quality.

7.4.3 Verification of purchased product
Incoming quality critical materials (including pre-printed labels) shall be physically or administratively quarantined until they have been tested or
otherwise verified and approved for use. Where quarantine is not feasible, e.g. for materials supplied via pipelines, the excipient manufacturer shall establish an agreement with the supplier so that they are notified of material that does not meet specification

The organization shall define and document the controls to verify the identity and quality of purchased product.

Sampling shall be conducted in accordance with a documented procedure designed to prevent contamination and cross-contamination.

Quality critical materials used in the manufacture of the excipient shall be tested or otherwise verified before use. Materials which are not sampled shall have alternative controls in place to assure their quality.

Bulk deliveries shall have controls to ensure freedom from contamination.

7.5 Production and service provision

7.5.1 Control of production and service provision

Controlled conditions shall include, as applicable:

a) The availability of information that specifies the characteristics of the product,
   No additional requirements to ISO 9001,

b) The availability of work instructions, as necessary,
   For batch processes documented instructions shall be issued to the production area. For continuous processes, there shall be a defined process and records shall be available.

Records shall be retained for each batch of excipient produced and shall include information relating to the production and control of the batch. Where critical to excipient quality records shall include:

- date/time each step was completed or date/time log of key parameters,
- identification of persons performing and directly supervising or checking each significant step, operation or control parameter,
- identification of major equipment and lines used,
- cleaning of equipment and utensils,
- conformance to specified operating ranges,
- material inputs to enable traceability (for example batch number and quantities of raw material/intermediate, time it was added, etc.),
- description of sampling performed,
- in process and laboratory control results,
- labelling control records,
- failures, deviation and their investigations,
- results of final product inspection.

and as applicable:

- the quantity produced for the defined batch and a statement of the percentage of theoretical yield,
- verification of the homogeneity of mixed batches.
Records of quality critical equipment use shall allow the sequence of cleaning, maintenance and production activities to be determined. Where multi-purpose equipment is in use records shall identify the previous usage.

Packaging and labelling controls shall be documented and shall ensure:

- packaging and labelling facilities are inspected immediately before use to ensure that materials that are not required for the current operation have been removed,
- correct labels are printed and issued containing the correct information,
- the information on the label shall be indelible,
- the correct label is applied to all containers,
- excess labels are immediately destroyed or returned to controlled storage.

Where solvents are recovered and reused they shall be controlled to ensure that they meet specifications appropriate for their reuse.

c) The use of suitable equipment,
The organization shall design and justify equipment cleaning and sanitization procedures and provide evidence of their effectiveness.

Equipment and utensils shall be cleaned, and where critical to excipient quality sanitised. The cleaning/sanitisation status of equipment shall be identified.

The frequency of equipment cleaning shall be determined by the organization and justified.

d) The availability and use of monitoring and measuring equipment,
No additional requirements to ISO 9001.

e) The implementation of monitoring and measurement,
Sampling methods shall be documented and shall define the time and location of sampling, and shall ensure that the sample is representative and clearly labelled. In-process samples shall not be returned to production for incorporation into the final batch.

f) The implementation of product release, delivery and post-delivery activities,
No additional requirements to ISO 9001.

7.5.2 Validation of processes for production and service provision
The consistent operation of the excipient manufacturing process shall be demonstrated based on knowledge of process parameters, product attributes and their inter-relationship.

Where the intent of blending or mixing is to ensure final batch uniformity, it shall be demonstrated that such processing achieves a state of homogeneity.

After significant changes, the impact on process capability shall be assessed.
7.5.3 Identification and traceability
Identification and traceability are specified requirements for quality critical raw materials, packaging materials, intermediates and finished excipients. Storage containers shall be identified and marked with their contents.

Records shall allow traceability of the excipient from raw materials through delivery to initial customers. The methods used for traceability and identification of raw materials used in excipients produced by continuous processing shall be defined.

The organization shall ensure there is a process to communicate the origin and traceability of the excipient to the customer.

Documents that facilitate traceability and COAs shall be provided for each delivery as agreed with the customer.

Excipient labels shall include:
- the name of the excipient and grade if applicable,
- the organization’s name and address,
- the batch number, and
- any special storage conditions, if applicable.

7.5.4 Customer property
No additional requirements to ISO 9001.

7.5.5 Preservation of product
Storage conditions shall be maintained. They shall be monitored and recorded if they are critical for the maintenance of packaging, raw material, intermediate or excipient quality characteristics. Deviations from specified storage conditions shall be assessed. Storage and handling procedures shall be defined in order to protect containers, labels and closures, minimise the risk of contamination, damage or deterioration of the excipient, and prevent mix ups.

There shall be a system in place to ensure that the excipient will be supplied within its expiry and/or retest interval.

Suppliers of transport services shall be provided with the required transport controlled conditions in order for them to maintain required conditions.

For bulk transport in non-dedicated equipment, verified cleaning procedures shall be applied between loadings, and a list of restricted and/or allowed previous cargoes shall be supplied to the transport companies. Records of cleaning shall be retained.

Steps shall be taken, such as tamper evident seals, to provide evidence of unauthorized access to the materials being transported.

The selection of excipient packaging systems shall be justified and documented by the organization. An excipient packaging system shall include the following features:
- written packaging specifications, including any special storage conditions required to preserve the packaging,
a) containers that do not interact with or contaminate the excipient,
b) tamper evident seals,
c) where containers are to be re-used for re-packaging, verified cleaning procedures including means of removing previous labels shall be applied. Records of cleaning shall be retained.

Note a tamper evident seal should have a distinct design and possess unique identifying characteristics that are difficult to duplicate. Each tamper evident seal should be traceable to and, where feasible, accounted for by the excipient manufacturer and should not be reusable once the seal is broken.

7.6 Control of monitoring and measuring equipment
No additional requirements to ISO 9001.

8 Measurement, analysis and improvement

8.1 General
No additional requirements to ISO 9001.

8.2 Monitoring and measurement

8.2.1 Customer satisfaction
No additional requirements to ISO 9001.

8.2.2 Internal audit
The organization shall conduct internal audits at planned intervals to determine whether the quality management system
conforms to the requirements of this Annex.

The criticality of the activity to the finished excipient quality shall be a factor in determining the frequency of audits.

8.2.3 Monitoring and measurement of processes
No additional requirements to ISO 9001.

8.2.4 Monitoring and measurement of product
Test methods shall be documented and suitable for their intended purpose.

If the organization claims the product is in compliance with a pharmacopoeia or an official compendium, then:

- non-compendial analytical tests shall be demonstrated to be at least equivalent to those in the compendia,
- the method shall comply with applicable general chapters and notices,
- the responsibility for monitoring the current pharmacopoeia or official compendium shall be assigned.

Written procedures shall be established to monitor and control the quality characteristics of excipients. These shall include, as applicable:

a) laboratory controls; including the preparation and use of laboratory solutions, reference standards,
i. laboratory controls shall include complete data derived from tests necessary to ensure conformance with specifications and standards. Records of these controls shall include:
   • identification and traceability of samples,
   • test method used,
   • raw data including sample preparation,
   • calculations performed,
   • test results and how they compare with established specifications,
   • name of the person who performed each test and the date(s) the tests were performed.

ii. there shall be a documented procedure and records for the preparation of laboratory reagents and solutions. Reagents and solutions shall be labelled with the name, concentration and expiry date.

iii. primary reference standards and purchased reagents shall be verified on receipt and appropriately stored. There shall be a documented procedure for the qualification of secondary reference standards against primary reference standards that includes their preparation, approval and storage. The re-evaluation period shall be defined for secondary reference standards and each batch shall be periodically re-qualified in accordance with a documented procedure.

b) excipient testing and release,

i. there shall be a procedure to ensure that appropriate manufacturing documentation, in addition to the conformance of test results to specifications is evaluated prior to release of the finished excipient. The Quality Unit shall be responsible for the release of the finished excipient.

   Note: for excipients produced by continuous processes assurance that the excipient conforms to documented specifications may be achieved through the results of in-process testing or other process monitoring measures.

c) investigation of out-of-specification test results,

i. out-of-specification (OOS) test results shall be investigated and documented according to a documented procedure.

   Where there is no assignable cause to invalidate the original results/data, the OOS procedure shall define the following at a minimum:
   
   a) statistical techniques that are to be used and under what circumstances,
   b) criteria for the use of retest sample results,
   c) criteria for resampling.

d) the retention of samples of each batch of the excipient,

i. a representative sample of each batch of the excipient shall be retained, unless otherwise justified and documented,
ii. for packaged excipients the retention period shall be justified and based on the expiry or re-evaluation,

iii. for bulk excipients the retention period shall be justified and based on the expiry or re-evaluation interval, or the duration of the shipment to the customer,

iv. shall be stored in a secured location, readily retrievable and in conditions consistent with the recommended storage conditions for the finished excipient,

v. the sample size shall be at least twice the amount required to perform complete specification testing.

e) preparation and issue of certificates of analysis, The Certificate of Analysis shall include at a minimum:

- excipient name and, if applicable, grade and compendial reference,
- manufacturer’s name and site of manufacture,
- date of manufacture,
- lot or batch number,
- expiration, retest or re-evaluation date,
- statement of compliance to the required specification,
- statement of compliance to this Annex,
- analytical results specific to the lot or batch, unless otherwise noted and explained,
- acceptance criteria,
- analytical method reference, and
- name and title of person authorizing the Certificate of Analysis.

f) the tests and limits for impurities,

i. excipient manufacturers shall identify and set appropriate limits for known impurities, and known objectionable microorganisms.

   Note: the limits should be based upon appropriate safety data, or limits as described in official guides and compendia (e.g. residual solvents and metal catalysts).

g) an evaluation of excipient stability,

i. the organization shall evaluate excipient stability based on historic data or specific studies. The organization shall define and justify an expiry or retest interval and ensure this is communicated to the customer.

8.3 Control of non-conforming product

Where applicable, the organization shall deal with nonconforming product by one or more of the following ways:

e) reprocessing shall only occur when it has been assessed that the excipient may be processed in that manner,

f) reworking shall only occur after the Quality Unit has documented a risk assessment, consideration shall be given to:
• new impurities that may be introduced as a result of reworking,
• additional testing to control the reworking,
• records and traceability to the original batches,
• suitable acceptance criteria for the reworked excipient,
• impact on stability or the validity of the re-evaluation interval, and
• impact on the performance of the excipient.

Following the risk assessment, controls to minimize the risks to excipient quality shall be documented and implemented.

g) blending of contaminated or adulterated batches to reduce the contamination or adulteration below an acceptable or detectable limit is not acceptable under this Annex.

Records of reprocessing and reworking activities shall be retained.

Incidences of non-conformance shall be investigated to assess the impact on other batches/products and on validated processes and activities.

There shall be a documented procedure defining how to manage excipient retrieval. All retrieval processes shall be documented, notified to the original manufacturer and records retained. Retrieved materials shall be identified and quarantined.

In case of a product non-conformance, an investigation shall be performed to establish whether any other batches are also affected.

Returned excipients shall be identified and controlled to prevent inadvertent use or release for sale until a documented evaluation of their quality has been completed by the Quality Unit. When conformance of a returned excipient has been confirmed and the intent is to make the returned excipient available for sale to another pharmaceutical customer, the evaluation shall consider its integrity and conformance to the required storage and/or transportation conditions throughout the supply chain. Records shall include the reason for return and the decision made as to the new disposition.

8.4 Analysis of data
No additional requirements to ISO 9001.

8.5 Improvement

8.5.1 Continual improvement
No additional requirements to ISO 9001.

8.5.2 Corrective action
No additional requirements to ISO 9001.

8.5.3 Preventive action
No additional requirements to ISO 9001.
Requirements for GDP for Pharmaceutical Excipients: Foreword

Many excipient manufacturers and distributors are already registered to ISO 9001:2008, “Quality Management Systems – Requirements”, and as a consequence EXCiPACT™ has developed this annex to that standard to allow such organizations to be assessed simultaneously to ISO 9001:2008 and to the requirements for GDP for pharmaceutical excipients. This annex to ISO 9001:2008 is based on the IPEC Good Distribution Practices Guide for Pharmaceutical Excipients 2006. The guidance (“how to do”) in that document has been converted to an auditable standard (“what to do”) and then the parts already covered by ISO 9001:2008 removed resulting in this annex.

Organizations that manufacture and distribute excipients can opt to be certified to this annex and the corresponding GMP Annex together or separately depending on their business arrangements.

The main text that follows is based on the headings in ISO 9001:2008 and the details are the GDP requirements:

Texts in Bold are ISO 9001:2008 Headings

Standard Texts are GDP requirements

Italicised text is taken directly from ISO 9001:2008 to provide context to the Annex statements which they immediately follow.

For full comprehension, this annex should be read in conjunction with ISO 9001:2008. A copy of that standard is not included herein for copyright and licensing reasons.
0 Introduction
This document is an Annex to ISO 9001:2008. Organizations requiring certification to this Annex shall hold an ISO9001 certificate issued under accreditation of an International Accreditation Forum member National Accreditation Body and covering the scope of manufacture and or distribution of relevant excipient products. Assessment against the requirements of this annex and ISO 9001:2008 may be conducted simultaneously.

Note Increasingly users of pharmaceutical excipients are required by the regulatory authorities to include audits of their suppliers into their supplier qualification process. The objective of these is standards is to reduce the number of these audits. EXCiPACT™ certification may not always be suitable for every customer’s supplier qualification requirements, so audits at suppliers of excipients critical to the users’ application may still be necessary.

0.1 General
Excipient distribution shall be carried out in accordance with Good Distribution Practices (GDP) consistent with this Annex. The objective of excipient GDP is to maintain pharmaceutical excipient quality and consistency, whilst ensuring traceability of the material throughout the entire supply chain.

Throughout this document, references to “GDP for pharmaceutical excipients” will be referred to as “GDP” and “excipients” to mean “pharmaceutical excipients”.

An excipient can only be assigned as pharmaceutical grade when it is in compliance with a pharmacopoeial specification (if existing for the specific excipient) and/or appropriate regulatory requirements and is manufactured, repackaged, and handled in accordance with excipient GMPs (e.g. EXCiPACT™, IPEC-PQG Excipient GMP, USP <1078>).

There shall be no upgrading of non-pharmaceutical grade product to pharmaceutical grade only on the basis of analytical testing and/or re-packing.

If there is no pharmaceutical grade product on the market then a non-pharmaceutical grade material can be utilised if:

- the manufacturer of the excipient is qualified (see 7.4.1),
- the excipient is prepared in accordance with the other relevant sections of this Annex,
- the non-pharmaceutical grade origin of the material is communicated to customers (see 7.2.3),
- the excipient is fully tested (see 8.2.4).

This document includes additional requirements that support the application of GDP to the supply of excipients. The section headings are consistent with those in ISO 9001:2008. Where a list does not start with “a)” then it is an addition to the text of the corresponding paragraph and preceding bullets in ISO 9001:2008, e.g. in 6.2.2, where the list starts with” f”). Where reference is made to ISO 9001 this means ISO 9001:2008.
0.2 Process approach
No additional requirements to ISO 9001.

0.3 Relationship with ISO 9004
No additional requirements to ISO 9001.

0.4 Compatibility with other management systems
No additional requirements to ISO 9001.

1 Scope

1.1 General
In this Annex the term “if/as applicable” is used several times. When a requirement is qualified by this phrase, it is deemed to be “applicable” unless the organization has a documented risk assessment which concludes that it is not applicable. This risk assessment shall also include operations covered in this Annex which are not carried out by the organization (outsourced).

Note: the “Matrix of Applicability” included as table 1 in the IPEC Good Distribution Practices Guide (GDP) may be used as guidance to determine applicability.

Purpose and scope
The scope of this Annex is the addition of GDP requirements for excipients to ISO 9001 requirements. These principles are to be applied by any party in the supply chain other than the original manufacturer of the excipients.

The Annex and its use
The Annex should be used in conjunction with the current IPEC Good Distribution Practices Guide for Pharmaceutical Excipients which provides detailed guidance.

1.2 Application
This Annex includes requirements additional to those required for ISO 9001 certification purposes and enables organizations to demonstrate conformity with GDP for excipients for the:
- transportation of bulk or packed excipients,
- warehousing (storage of packed excipients),
- brokering, trading, and reselling of packed excipients,
- packaging, re-packaging and processing,
- sampling, testing, and retesting,
- relabelling,
- bulk handling and bulk storage.

2 Normative references
ISO 9001:2008, Quality Management Systems - Requirements

3 Terms and definitions
See section Definitions and References.

Pharmaceutical excipients
Pharmaceutical excipients are substances other than the Active Pharmaceutical Ingredient (API) which have been appropriately evaluated for safety and are intentionally included in a drug delivery system.

4 Quality management system

4.1 General requirements
Where manufacturing, testing or other operations that could affect excipient quality are outsourced the organization shall:

a) define the responsibility for quality and the control measures within the quality management system (see also 7.4),
b) demonstrate that the applicable GDP principles in accordance with this Annex are applied to those operations.

Note: quality risk management can be useful for identifying and prioritising areas for continual improvement.

4.2 Documentation requirements

4.2.1 General
The design, organization and documentation of the quality system shall be structured to facilitate common understanding and consistent application.

The Quality Management system documentation shall include:

e) the organization’s overall intentions and approach to GDP,
f) documented procedures required for conformance to this Annex,
g) a documented risk assessment that defines and justifies when the “as applicable” clauses in this Annex are not implemented.

4.2.2 Quality Manual
The organization shall establish and maintain a quality manual that includes or references:

d) a definition of the extent to which this Annex applies to its quality management system and its business processes.

4.2.3 Control of documents
Documents that impact product quality shall have a defined owner.

The Quality Unit shall review and approve documents that impact product quality, including changes to these documents.

Note: the Quality Unit may delegate this activity, unless otherwise noted herein if appropriate controls are in place and are documented (see 5.5.1).

Electronic documentation shall meet the requirements stated above.

If electronic signatures are used on documents they shall be controlled to be as secure as a hand written signature.

Note: electronic documents and signatures may also need to satisfy local regulatory requirements.
4.2.4 Control of records
The organization shall define which records, results and reports of subcontractor activities shall be retained and by whom.

Electronic records shall be subject to the same controls as those required for other records.

Entries in quality records shall be clear, indelible and made directly after performing the activity (in the order performed), signed or initialled and dated by the person performing the activity and making the entry. Corrections to entries shall be signed or initialled and dated, leaving the original entry legible.

The record retention period shall not be less than one year past the excipient’s expiry or first re-evaluation date. If the manufacturer does not stipulate an expiry or re-revaluation date, the record retention period shall be five years from the date of manufacture.

Certificates of Analysis (COAs) and Certificates of Conformity (COCs) are records that are required to ensure product traceability back to the original manufacturer. Documented procedures shall be implemented to ensure control of COAs.

4.3 Change Control
There shall be a documented procedure for the evaluation defining the responsibilities and requirements and approval of changes that may impact the quality of the excipient including the impact on any regulatory submissions made by the excipient supplier. Evaluation and approval of changes shall occur prior to implementation. The Quality Unit shall approve significant changes that may impact on the quality of the excipient. Where the impact on the quality of the excipient is determined to be significant, such changes shall be communicated in advance whenever possible to customers and, as applicable, regulatory authorities (see 7.2.3). Records of the change control process shall be retained.

The impact of changes on validated processes and activities shall be assessed (see 7.5.2).


Note 2: quality risk management can be utilized to evaluate proposed changes. The level of effort and formality of the evaluation be commensurate with the level of risk.

5 Management responsibility

5.1 Management commitment
Top management shall provide evidence of its commitment to the development and implementation of the quality management system and continually improving its effectiveness by:

f) ensuring that GDP objectives are established,

g) communicating to the organization the importance of conforming to the requirements of this Annex.
5.2 Customer focus
Top management shall ensure that customer requirements related to GDP for pharmaceutical excipients are determined, agreed with the customer and met.

5.3 Quality Policy
Top management shall ensure that the quality policy:

f) includes a commitment to comply with GDP requirements.

5.4 Planning

5.4.1 Quality objectives
Top management shall set objectives for adherence the requirements of this Annex.

5.4.2 Quality Management system planning
No additional requirements to ISO 9001.

5.5 Responsibility, authority and communication

5.5.1 Responsibility and authority
An independent quality unit shall be responsible at a minimum for:

- ensuring quality critical activities are identified and undertaken as defined,
- approving suppliers of excipients, quality critical materials and services,
- reviewing batch records to ensure any deviations are fully investigated,
- ensuring corrective and preventive actions are implemented,
- approving or rejecting packaging components and excipients,
- approving significant changes to quality critical equipment, processes, specifications, procedures, and test methods (see 4.3),
- approving the results of investigations into deviations from process instructions, test or measurement failures, and complaints,
- developing and implementing an internal audit program,
- ensuring that providers of outsourced services have agreed to comply with the relevant sections of this Annex.

The Quality Unit may delegate some of these activities if appropriate controls are in place and are documented.

The independence of the Quality Unit shall be documented and demonstrated by showing the inter-departmental relationships as well as relationship to top management.

5.5.2 Management representative
Top management shall appoint a member of the organization’s management who irrespective of other responsibilities, shall have the responsibility and authority that includes:

d) ensuring the promotion and awareness of regulatory requirements throughout the organization.

5.5.3 Internal communication
GDP and regulatory requirements shall be communicated as applicable throughout the organization.
Top management shall be promptly notified about any quality critical situations in accordance with a documented procedure (for example those that would lead to a product recall from the market).

5.6  Management review

5.6.1  General

Note: necessary changes identified in the management review should be assessed and implemented via the change control procedure (4.3).

5.6.2  Review input
The input to management review shall include information on

h) new, revised or proposed regulatory requirements.

5.6.3  Review output
The output from this management review shall include any decisions and actions related to

d) improvements necessary as a result of regulatory requirements

6  Resource management

6.1  Provision of resources
The organization shall determine and provide the resources needed:

c) to meet the GDP requirements in this Annex which have been determined to be applicable.

6.2  Human resources

6.2.1  General
Personnel whose role has an impact on excipient quality shall have written job descriptions.

Consultants advising on the design, production, packaging, testing or storage of excipients shall have sufficient education, training and experience or any combination thereof to advise on the subject for which they are retained. Records shall be maintained listing the name, address and qualifications of consultants providing advice concerning any aspect of this Quality Management System and the type of service they provide.

6.2.2  Competence, training and awareness
The organization shall:

f) ensure training, including the requirements of this Annex as it relates to the employee's function, is conducted by qualified individuals,

g) ensure training is conducted prior to carrying out the assigned duties,

h) ensure training includes

   i. GDP principles and the contents of this Annex,

   ii. the risk of contamination to excipient quality,

   iii. the potential hazard to end customer/patient if an excipient is contaminated,

   iv. potential impact on product quality and use due to departures from specified procedures,
v. the risk of excipient contamination from deficiencies in personal hygiene, environment conditions,
vi. the reporting of significant failures and deviations from procedures including the impact they may have on excipient quality.

i) ensure GDP refresher training is conducted with sufficient frequency to ensure that employees remain familiar with applicable elements of this Annex.

6.2.3 Personnel Hygiene
To protect excipients from contamination, the organization shall conduct a risk assessment to identify areas in which the excipient is at risk of contamination from personnel or their activities. The following shall be considered at a minimum to prevent excipient contamination:

a) the personnel themselves and their attire, including personal protective equipment,
b) loose items, including those in pockets,
c) unauthorized access to designated areas (see 6.3),
d) the potential impact of any person with an apparent illness or open lesions,
e) the storage and use of food, drink, personal medication, tobacco products or similar items.

Where existing controls to minimize the risks of excipient contamination are not considered effective then additional measures shall be documented and implemented.

6.3 Infrastructure
The infrastructure shall be designed, operated, cleaned and maintained to avoid contamination and mix-ups of the excipient.

The organization shall conduct a risk assessment based on the organization’s intended use of the infrastructure to identify areas in which the excipient is at risk for contamination from deficiencies in buildings and/or facilities. The risk assessment shall consider the following at a minimum to identify where the excipient is at risk from contamination:

a) location of the operations (e.g. internal, external),
b) state of repair of the building and facility,
c) suitable size, construction and location,
d) ability to maintain a suitably clean building and facility environment,
e) operations that can affect the excipient quality,
f) presence of airborne contaminants, especially highly sensitizing or toxic substances.

Where existing controls to minimize the risks of excipient contamination are not considered effective then additional measures shall be documented and implemented.

There shall be controls to ensure that defective equipment shall not be used.
Equipment which may impact excipient quality shall be commissioned before initial use to ensure that it is functioning as intended.

Equipment shall be placed and constructed to facilitate cleaning and maintenance. The use, cleaning and maintenance of quality critical equipment shall be recorded. The status of equipment shall be readily identifiable. Equipment shall be constructed so that contact surfaces will not be reactive, additive, or absorptive.

Processes associated with highly sensitizing or toxic materials shall be separated from those used for excipients, unless measures to prevent cross-contamination have been implemented and the effectiveness of these measures have been demonstrated.

The organization shall conduct a risk assessment considering the risk to excipient quality from utilities and process materials (e.g. nitrogen, compressed air, steam, lubricants etc.) used in the production, storage or transfer of materials. Suitable control measures shall be implemented to mitigate the identified risks.

Computerized systems that may impact upon excipient quality shall have documented controls for operation, maintenance, back-up or archiving, disaster recovery and include measures to prevent unauthorized access or changes to software, hardware or data. Changes to computerized systems that may impact upon excipient quality shall be verified and documented (see section 4.3).

Water, where used in contact with excipients shall conform to written specifications and be monitored to be of a suitable quality for its intended use. Unless otherwise justified, water shall, at a minimum meet WHO guidelines for drinking (potable) water quality.

If interruptions in supply or deviations in the quality of such water occur, evidence and appropriate rationale shall be documented to show such interruptions have not compromised the quality of the excipient.

Product contact water shall be produced and distributed in such a manner so as to prevent contamination entering, or backflows in the system.

Access to areas of the buildings and facilities designated as limited access areas shall be controlled.

6.4 Work environment

The work environment shall be managed and controlled to minimize risks of excipient contamination. A documented risk assessment shall be carried out to determine the necessary controls.

The documented risk assessment shall cover the following controls, as applicable:

a) air handling systems,
b) special environments,
c) cleanliness and sanitary conditions,
d) waste segregation and disposal,
e) pest control,
f) other risk assessments required by this Annex.

Where maintenance of the work environment is critical to excipient quality, the controls shall be documented.

### 6.4.1 Air Handling
Where the risk assessment has identified the need for an air handling system, it shall be designed and maintained to assure adequate protection of the excipient. The effectiveness shall be demonstrated.

### 6.4.2 Controlled Environment
Where the risk assessment has identified the need for a controlled environment, it shall be monitored to assure product quality. Where an inert atmosphere is required, the gas shall be treated as a quality critical raw material (see 7.4.3) or intermediate.

If interruptions in the controlled environment occur, the organization shall perform an investigation. Evidence and appropriate rationale shall be documented to show that such interruptions have not compromised the quality of the excipient.

### 6.4.3 Cleaning and Sanitary Conditions
Where the risk assessment (see 6.4) has identified the need for clean and sanitary conditions, the organization shall document procedures assigning responsibility for cleaning and sanitation. Cleaning records shall be maintained. Waste shall be segregated and disposed of in a timely and appropriate manner. If waste is not disposed of immediately, it shall be suitably identified.

### 6.4.4 Pest Control
Where the risk assessment (see 6.4) has identified the need for pest control, the organization shall document the pest control program.

### 6.4.5 Lighting
Adequate lighting shall be provided to facilitate cleaning, maintenance and proper operations. Where the excipient is exposed to the work environment or stored, lighting shall be shatter-proof or otherwise protected.

### 6.4.6 Drainage
In areas where the excipient is exposed to the work environment or stored, drains shall be of adequate size. Drains connected directly to a sewer shall be provided with an air break or other mechanical device to prevent back-siphoning.

### 6.4.7 Washing and Toilet Facilities
Personnel washing facilities shall be provided which ensure suitable hygiene standards shall be maintained. Clean toilet facilities shall be separate from but easily accessible to working areas. Facilities for showering and/or changing clothes shall be provided, where identified in the personnel hygiene risk assessment (see 6.2.3).
7 Product realization

7.1 Planning of product realization

In planning product realization, the organization shall determine the following, as applicable and appropriate:

e) documented testing programs for quality critical materials that include appropriate specifications, sampling plans, test and release procedures,

f) environmental and hygiene control programs to minimize risks of contamination of the excipient,

g) documented procedures describing activities relating to the storage and distribution of excipients,

h) including implementation of identified actions from risk assessments described in other sections of this Annex.

7.2 Customer-related processes

7.2.1 Determination of requirements related to the product

Statutory and regulatory requirements related to the product shall include as a minimum:

- Compendial general requirements, including TSE/BSE,
- Residual Solvents,
- Elemental impurities.

Changes requiring notification and/or documented prior approval from the customer shall be determined.

7.2.2 Review of requirements related to the product

No additional requirements to ISO 9001.

7.2.3 Customer communication

The organization shall determine and implement effective arrangements for communicating with customers in relation to:

d) significant changes (See also 4.3. and 7.2.1),

e) critical deviations which become known after delivery of the excipient (see 7.2.1 and 7.2.3),

f) product recall,

g) the transfer of information throughout the entire supply chain, including quality or regulatory information, from the original manufacturer of the excipient to the final customers,

h) each batch shipped regarding the original manufacturer and the manufacturing site(s) as well as expiry and/or retest dates.

Certificates of Analysis that are traceable to the manufacturer’s original COA shall be provided for each batch shipped. The original manufacturer’s identity and production site shall be communicated to the customer.

7.3 Design and development

No additional requirements to ISO 9001.
7.3.1 Design and development planning
No additional requirements to ISO 9001.

7.3.2 Design and development inputs
No additional requirements to ISO 9001.

7.3.3 Design and development outputs
No additional requirements to ISO 9001.

7.3.4 Design and development review
No additional requirements to ISO 9001.

7.3.5 Design and development verification
No additional requirements to ISO 9001.

7.3.6 Design and development validation
No additional requirements to ISO 9001.

7.3.7 Control of design and development changes
No additional requirements to ISO 9001.

7.4 Purchasing

7.4.1 Purchasing process
Quality critical materials and services shall be identified and justified.

Note risk assessment techniques are a useful way of identifying quality critical materials and services.

Suppliers of quality critical materials, including all excipients and services shall be approved by the Quality Unit after a documented evaluation of the supplier’s quality management system, including adequate evidence that they can consistently meet agreed requirements.

The organization shall require that contract manufacturers or laboratories adhere to the relevant sections of this Annex (See 4.1).

Where purchased, primary packaging material specifications shall be established and a written procedure shall clearly define primary packaging materials for each individual excipient based upon the excipient’s properties and stability.

7.4.2 Purchasing information
The organization shall require that it is notified by its suppliers of any significant change to the excipient that may impact quality or functionality.

Any GDP or GMP relevant activity outsourced to another party shall be agreed upon in a written contract including the application of the relevant parts of this annex.

7.4.3 Verification of purchased product
Incoming quality critical materials (including pre-printed labels and all excipients) shall be physically or administratively quarantined until they have been tested or otherwise verified and approved for use. Where quarantine is not feasible, the organization shall establish an agreement with the supplier so that they are notified of material that does not meet specification.
The organization shall define and document the controls required to verify the identity and quality of purchased products.

Materials which are to be transferred into another container shall be sampled and tested. Key parameters shall be tested to verify the identity and quality of such material.

Sampling shall be conducted in accordance with a documented procedure designed to prevent contamination and cross-contamination.

Materials which are not sampled shall have controls in place to ensure their quality.

Bulk deliveries shall have controls to ensure freedom from contamination.

7.5 Production and service provision

7.5.1 Control of production and service provision

Controlled conditions shall include, as applicable:

a) The availability of information that specifies the characteristics of the product
   No additional requirements to ISO 9001.

b) The availability of work instructions, as necessary,
   For re-packaging and other manufacturing operations written instructions shall be made available to the operator.

Records shall be retained for each batch of excipient and shall include information relating to the handling and control of the batch. Where applicable and critical to excipient quality records shall include:

- date/time each step was completed or date/time log of key parameters,
- identification of persons performing and directly supervising or checking each significant step, operation or control parameter,
- identification of major equipment and lines used,
- cleaning of equipment and utensils,
- conformance to specified operating ranges,
- material inputs to enable traceability, for example batch number and quantities,
- description of sampling performed,
- in process and laboratory control results,
- labelling control records,
- failures, deviation and their investigations,
- results of final product inspection.

Records of quality critical equipment use shall allow the sequence of cleaning, maintenance and operational activities to be determined. Where multi-purpose equipment is in use records shall identify the previous usage.

Packaging and labelling controls shall be documented and shall ensure:

- packaging and labelling facilities are inspected immediately before use to ensure that materials that are not required for the current operation have been removed,
- correct labels are printed and issued containing the correct information,
• the information on the label shall be indelible,
• the correct label is applied to all containers,
• excess labels are immediately destroyed or returned to controlled storage.

c) The use of suitable equipment,
The organization shall design and justify equipment cleaning and sanitization procedures and provide evidence of their effectiveness.

Equipment and utensils shall be cleaned, and where critical to excipient quality sanitised. The cleaning/sanitisation status of equipment shall be identified.

For dedicated equipment the frequency of equipment cleaning shall be determined by the organization and justified.

d) The availability and use of monitoring and measuring equipment,
No additional requirements to ISO 9001.

e) The implementation of monitoring and measurement,
Sampling methods shall be documented and shall define the time and location of sampling, and shall ensure that the sample is representative and clearly labelled. Samples shall not be returned to the batch.

f) The implementation of product release, delivery and post-delivery activities,
No additional requirements to ISO 9001.

7.5.2 Validation of processes for production and service provision
Where the intent of blending or mixing is to ensure final batch uniformity, it shall be demonstrated that such processing achieves a state of homogeneity.

7.5.3 Identification and traceability
The original manufacturer, intermediaries and handling operations of the excipient shall always be traceable and the information made available to regulatory authorities and customers, both downstream and upstream.

Storage containers shall be identified and marked with their contents.

The organization shall ensure there is a process to communicate the origin and traceability of the excipient to the customer.

Excipient labels shall include:
a) the name of the excipient and grade if applicable,
b) the organization’s and/or manufacturer’s name and address,
c) the batch number,
d) any special storage conditions, if applicable.

7.5.4 Customer property
No additional requirements to ISO 9001.

7.5.5 Preservation of product
Storage conditions shall be maintained. They shall be monitored and recorded if they are critical for the maintenance of packaging, raw material,
intermediate or excipient quality characteristics. Deviations from specified storage conditions shall be assessed. Storage and handling procedures shall be defined in order to protect containers, labels and closures, minimise the risk of contamination, damage or deterioration of the excipient and prevent mix-ups.

There shall be a system in place to ensure that the excipient will be supplied within its expiry and/or retest interval.

Suppliers of transport services shall be provided with the required transport controlled conditions in order for them to maintain required conditions.

For bulk transport in non-dedicated equipment, verified cleaning procedures shall be applied between loadings, and a list of restricted and/or allowed previous cargoes shall be supplied to the transport companies. Records of cleaning shall be retained.

Steps shall be taken, such as tamper evident seals, to provide evidence of unauthorized access to the materials being transported.

The selection of excipient packaging systems shall be justified and documented by the organization. An excipient packaging system shall include the following features:

a) written packaging specifications, including any special storage conditions required to preserve the packaging,
b) containers that do not interact with or contaminate the excipient,
c) tamper evident seals,
d) where containers are to be re-used for re-packaging, verified cleaning procedures including means of removing previous labels shall be applied. Records of cleaning shall be retained.

Note a tamper evident seal should have a distinct design and possess unique identifying characteristics that are difficult to duplicate. Each tamper evident seal should be traceable to and, where feasible, accounted for by the excipient manufacturer and should not be reusable once the seal is broken.

7.6 Control of monitoring and measuring equipment
No additional requirements to ISO 9001.

8 Measurement, analysis and improvement

8.1 General
No additional requirements to ISO 9001.

8.2 Monitoring and measurement

8.2.1 Customer satisfaction
No additional requirements to ISO 9001.

8.2.2 Internal audit
The organization shall conduct internal audits at planned intervals to determine whether the quality management system

c) conforms to the requirements of this Annex.
The criticality of the activity to the finished excipient quality shall be a factor in determining the frequency of audits.

**8.2.3 Monitoring and measurement of processes**
No additional requirements to ISO 9001.

**8.2.4 Monitoring and measurement of product**
Test methods shall be documented and suitable for their intended purpose.

If the organization claims the product is in compliance with a pharmacopoeia or an official compendium, then:

- non-compendial analytical tests shall be demonstrated to be at least equivalent to those in the compendia,
- the method shall comply with applicable general chapters and notices.
- the responsibility for monitoring the current pharmacopoeia or official compendium shall be assigned.

Written procedures shall be established to monitor and control the quality characteristics of excipients. These shall include, as applicable:

a) laboratory controls; including the preparation and use of laboratory solutions, reference standards,
   i. laboratory controls shall include complete data derived from tests necessary to ensure conformance with specifications and standards. Records of these controls shall include:
      - identification and traceability of samples,
      - test method used,
      - raw data including sample preparation,
      - calculations performed,
      - test results and how they compare with established specifications, and
      - name of the person who performed each test and the date(s) the tests were performed.
   there shall be a documented procedure and records for the preparation of laboratory reagents and solutions. Reagents and solutions shall be labelled with the name, concentration and expiry date.
   ii. primary reference standards and purchased reagents shall be verified on receipt and appropriately stored. There shall be a documented procedure for the qualification of secondary reference standards against primary reference standards that includes their preparation, approval and storage. The re-evaluation period shall be defined for secondary reference standards and each batch shall be periodically re-qualified in accordance with a documented procedure.

b) excipient testing and release,
   ii. there shall be a procedure to ensure that appropriate manufacturing and/or packaging documentation, in addition to the conformance of test results to specifications is evaluated prior to release of the
The Quality Unit shall be responsible for the release of the finished excipient.

c) investigation of out-of-specification test results,
   ii. out-of-specification (OOS) test results shall be investigated and documented according to a documented procedure.

Where there is no assignable cause to invalidate the original results/data, the OOS procedure shall define the following at a minimum:

a) statistical techniques that are to be used and under what circumstances,

b) criteria for the use of retest sample results,

c) criteria for resampling.

d) the retention of samples of each batch of the excipient,
   i. when repackaged, a representative sample of each batch of the excipient shall be retained.
   ii. for packaged excipients the retention period shall be justified and based on the expiry or re-evaluation date,
   iii. for bulk excipients the retention period shall be justified and based on the expiry or re-evaluation interval, or the duration of the shipment to the customer,
   iv. shall be stored in a secured location, readily retrievable and in conditions consistent with the recommended storage conditions for the finished excipient,
   v. the sample size shall be at least twice the amount required to perform complete specification testing.

e) preparation and issue of certificates of analysis,

The Certificate of Analysis shall include at a minimum:

- excipient name and, if applicable, grade and compendial reference,
- manufacturer’s name and site of manufacture,
- date of manufacture,
- lot or batch number,
- expiration, retest or re-evaluation date,
- statement of compliance to the required specification,
- statement of compliance to this Annex,
- analytical results specific to the lot or batch, unless otherwise noted and explained,
- acceptance criteria,
- analytical method reference, and
- name and title of person authorizing the Certificate of Analysis.

f) an evaluation of excipient stability,
   i. where excipients are repackaged there shall be documented evidence that their stability has not been adversely affected and specified expiry dates or retest intervals are justified.
8.3 Control of non-conforming product
Where applicable, the organization shall deal with nonconforming product by one or more of the following ways:

- e) rejection,
- f) downgrading to a grade of lower quality,
- g) return of the material to the original manufacturer,
- h) disposal,
  - i) blending of contaminated or adulterated batches to reduce the contamination or adulteration below an acceptable or detectable limit is not acceptable under this Annex.

Note: out of specification batches may be re-worked or re-processed to meet agreed specifications (for more details see the EXCiPACT™ GMP standard).

There shall be procedures for the holding, testing, and downgrading of non-conforming excipient.

Incidences of non-conformance shall be investigated to assess the impact on other batches/products and on validated processes and activities.

Customer complaints and information about possible defects shall be systematically investigated and documented, based on a written procedure with assigned responsibilities.

There shall be a documented procedure defining how to manage the retrieval of a pharmaceutical excipient. All retrieval processes shall be documented, notified to the original manufacturer and records retained. Retrieved materials shall be identified and quarantined.

In case of a product non-conformance, an investigation shall be performed to establish whether any other batches are also affected.

Returned excipients shall be identified and controlled to prevent inadvertent use or release for sale until a documented evaluation of their quality has been completed by the Quality Unit(s). When conformance of returned excipient has been confirmed and the intent is to make the returned excipient available for sale to another pharmaceutical customer, the evaluation shall consider its integrity and conformance to the required storage and/or transportation conditions throughout the supply chain. Records shall include the reason for return and the decision made as to the new disposition.

8.4 Analysis of data
No additional requirements to ISO 9001.

8.5 Improvement

8.5.1 Continual improvement
No additional requirements to ISO 9001.

8.5.2 Corrective action
No additional requirements to ISO 9001.

8.5.3 Preventive action
No additional requirements to ISO 9001.
Requirements for Auditor Qualification and Auditing Excipient Suppliers: Introduction

This document is an Annex to ISO 19011:2002, Guidelines for quality and/or environmental management systems auditing, as this is the most appropriate publicly available document and the most commonly used by 3rd party audit organizations. The headings and sections in this document are those of ISO 19011:20021 and any additional text stipulates requirements that need to be implemented along with the ISO 19011:2002 clauses in order to perform EXCiPACT™ GMP and GDP certification assessments. Although ISO 19011:2002 is written as guidance all 3rd party audit organizations offering EXCiPACT™ certification will be expected to comply with all clauses, plus those in this Annex.

Where a heading or section of ISO 19011:2002 is omitted then there are no additional requirements to those already stipulated in ISO 19011:2002. Text in italics is a summary of the main features of the relevant clauses in ISO 19011:2002 and is provided as an aid to comprehension of the additional requirements in this Annex.

Thus the requirements in this document will be simple to implement in organizations that are already using ISO 19011:2002 as the basis of their auditing and for defining auditor competency.

These additional requirements have been defined by EXCiPACT™ so that auditors are able to lead and conduct audits using the definitions of Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) in the Excipient Certification Scheme. The requirements in this document constitute a definition of auditor competency.

The regulatory authorities who are responsible for the safety of pharmaceuticals have consistently signalled that a suitable 3rd party audit scheme would be acceptable as a means of assuring the quality and GMP requirements of pharmaceutical excipients – but only if the auditors are of a suitable calibre in terms of knowledge, experience and expertise. Thus organizations wishing to offer 3rd party certification based upon audits using the GMP and GDP standards in this scheme will also have to ensure their auditors meet the requirements in this document.

The document defines the requirements to be met by auditors in order for them to conduct audits of manufacturers of excipients according to GMP and audits of distributors/traders of excipients according to GDP. To carry out only GDP audits of distributors/traders of excipients the principles of auditing (section 4) and management of the audit program (section 5) are the same, but only the general and the GDP related requirements in section 6, section 7 and appendix A need to be met. Section 7.4.4 b) gives the details related to education and experience required for GDP auditors.

The appendix to this document provides guidance on the topics in this document and also sets out the minimum study requirements for...
excipient auditors. This appendix can be used to develop suitable training programmes to qualify auditors.

The overall arrangements for conducting audits and for delivering certification are covered in the following sections of EXCiPACT™.

EXCiPACT™ will require all certification bodies to comply with these requirements.
1 **Scope**

ISO 19011:2002 provides guidance on how to audit an organization’s quality or environmental system. It describes the principles of auditing, managing audit programs, and the criteria for auditor competency. In the context of EXCiPACT™ audits, it indicates that the auditors shall have the necessary knowledge and understanding of the principles and application of GMP and GDP.

These requirements apply to auditors assessing an organization’s quality management system against the requirements in the EXCiPACT™ GMP and GDP Annexes. In addition, those personnel making the certification decision in the 3rd party audit organization shall also comply with these requirements.

2 **Normative references**

ISO 19011:2002 Guidelines for quality and /or environmental management system auditing.

EU Guide to GMP Part 1 Chapter 4 and 21CFR 211.188

3 **Terms and Definitions**

The terms and definitions in ISO 19011:2002 apply.

4 **Principles of Auditing**

Section 4 describes how the organization adopts the principles of good auditing practice to ensure reliable and consistent audits and audit outcomes. The section describes the prerequisites which shall be implemented to ensure that audits generate relevant conclusions and that different auditors can reach the same conclusions given the same circumstances.

All auditors shall follow and adopt the following principles:

   a) Ethical Conduct
      - Will not accept any inducements that may affect decision-making.
      - Will not disclose any information to a third-party without written authorization.

   b) Fair Presentation
      - No additional requirements

   c) Due Professional Care
      - Will only undertake assignments for which they are qualified (e.g. GMP, GDP).

   d) Independence:
      - Will have no conflict of interest with the party being audited
        1. No financial incentive,
        2. No personal interest,
        3. No consulting in the area of the audit within the previous 2 years or the following 2 years,
      - Will be financially independent of the party being audited,
      - Will be independent of the organization being audited,
5 Managing an Audit Programme

5.1 General
Section 5 defines an audit programme, and goes onto indicate that the audit organization’s top management shall define who is responsible for managing such programme(s). The audit programme follows the “Plan, Do, Check, Act” approach embodied in ISO 9001:2008 and describes each of these phases.

No Additional requirements.

5.2 Audit Programme objectives and extent
The organization shall set objectives and define the scope for the audit programme as a prerequisite for directing audit planning and implementation activities.

5.2.1. The Objectives of an Audit Programme are to:
- Verify conformance of the auditee’s quality system to Excipient GMP and/or GDP requirements so as to confirm the excipient is suitable for its intended use in the dosage form (where known).
- Confirm that the site has the ability to consistently produce the intended excipient.
- Confirm that the site has the ability to consistently handle and control the intended excipient during the supply chain.

5.2.2. The extent of the Audit Programme shall include:
- All excipients and related operations to be certified.
- The degree of supply chain assessment as indicated in the application scope.
- At least an annual site audit.

5.3 Audit Programme Responsibilities, Resources, and Procedures
The organization shall manage audit programmes by allocating individuals with knowledge and understanding of auditing, management skills and technical and business understanding relevant to the activities to be audited.

5.3.1 Audit Programme Responsibilities
Shall be in conformance with ISO 19011:2002 and this Annex.

5.3.2 Audit Programme Resources
- Auditors shall meet the requirements of competency set out in Section 7,
- The audit team shall have the expertise to properly assess all operations within the scope of the certification,
- Where the audit is conducted by a sole auditor, that individual shall have the skills to conduct the audit and write the audit report.

5.3.3 Audit Programme Procedures
- The auditee and the auditors shall be notified of the intended auditors prior to the assessment,
- Both the auditors and the auditee shall notify the 3rd party audit
organization if there is any conflict of interest in the assignment of these auditors,

- If there is any conflict of interest, then other auditors shall be allocated.

5.4 Audit Programme Implementation
Documented procedures are required to define the audit programme elements.

The guidance in ISO 19011:2002 shall be followed for conducting audits. The formality required will depend upon the size and culture of the auditee.

5.5 Audit Programme Records
Records of audit activities shall be retained to demonstrate audit programmes have been implemented as intended.

Programme records shall conform to Good Documentation Practices.

5.6 Audit Programme Monitoring And Reviewing
The audit organization shall periodically monitor, review and report to top management, that audit programmes and objectives have been satisfied. Opportunities for improvement of audit programmes shall be identified as part of this review process.

The following indicators of non-conformance of the quality system shall be monitored to identify changes to the audit programme since they may influence the quality system audit:

- Complaints from customers,
- Adverse findings from Regulatory inspections of the auditee,
- Market withdrawal (recall) of an excipient lot.

6 Audit activities

6.1 General
Section 6 describes the core requirements relating to initiating, preparing for and performing the audit, together with the post audit process. It also emphasises the importance of effective communication both with the auditee and other audit team members if involved.

No additional requirements.

6.2 Initiating the audit
The Audit team leader shall be competent at establishing and implementing an audit programme which shall be capable of meeting defined objectives and gains acceptance from the auditee.

6.2.1. Appointing The Audit Team Leader
The Audit Team Leader shall

- Hold an established qualification of specific GMP and/or GDP audit experience and meet the competency criteria in Section 7 as well as at least one of the following:
  - be registered as a quality Lead Auditor by an accredited certification body,
be registered with a recognised auditor registration organization,
(e.g. International Register of Certificated Auditors (IRCA), American Society for Quality (ASQ)),
have demonstrated their ability to perform audits such as to ISO 9001:2008, ISO 14001 audits, or pharmaceutical or excipient or API GMP/GDP audits

6.2.2. Defining Audit Objectives, Scope, and Criteria
The audit shall evaluate the following:
• GMP where the applicant is a manufacturer,
• GDP where the applicant is a distributor or where distribution is within scope
• All operations either on site or outsourced which are performed to produce the excipient from the point where full GMP begins through to storage and shipment of the packaged excipient.

6.2.3. Determining the Feasibility of the Audit
No additional requirements

6.2.4. Selecting the Audit Team
• The scope of the audit shall be used to determine the number of auditors required so that the duration minimizes the impact to site operations (see Conformity Assessment Requirements section in EXCiPACT™ for details of audit durations),
• The audit team shall include at least one EXCiPACT™ qualified auditor meeting the auditor competency criteria in Section 7. All members of the audit team shall be EXCiPACT™ trained pending qualification. There shall be a minimum of one qualified auditor per non-qualified auditor on the team.

6.2.5. Establishing Initial Contact with the Auditee
The audit team leader shall communicate with the site representative concerning:
• Security requirements such as auditor identification, carrying electronic devices including cell phone, and a camera.
• Confirmation of the scope of the audit and any off-site operational activities such as packaging, warehousing, and testing.
• Inquire about the need for the execution of additional confidentiality requirements, in order to establish the ability to take copies of evidence with the auditor, e.g. pictures/images, sample documents,
• The presence of any allergenic or sensitising materials on site which may pose a hazard to the audit team.

6.3 Conducting document review
The audit team leader shall request the following additional documentation for review prior to the site audit (where available):
• A completed pre-audit questionnaire,
• Flow diagram(s) showing key processes,
• List of procedures supporting the GMP/GDP quality system,
• Quality Manual for the GMP/GDP quality system and/or Site Master File,
• Site map showing the layout and size of the excipient operations conducted at the facility,
• Current organization chart.

6.4 Preparing for the on-site audit activities

6.4.1 Preparing the Audit Plan
The Audit objectives shall not include the preparation of recommendations.

6.4.2 Assigning Work to the Audit Team
No additional requirements

6.4.3 Preparing Work Documents
• Preparation of a checklist is good practice.

Note: The IPEC-PQG GMP Excipient Auditing Guide and the IPEC GDP Excipient Auditing Guides are helpful in the development of checklists.

6.5 Conducting on-Site Audit Activities

6.5.1 Conducting the Opening Meeting
The purpose of an opening meeting is:
e) to inform the auditee of the process for discussing the audit and agreeing audit findings.

6.5.2 Communication During the Audit
No additional requirements

6.5.3 Roles and Responsibilities of Guides and Observers
No additional requirements

6.5.4 Collecting and Verifying Information
No additional requirements

6.5.5 Generating Audit Findings
No additional requirements

6.5.6 Preparing Audit Conclusions
• Audit conclusions shall be limited to the type of audit and scope, and shall not include recommendations.

6.5.7 Conducting the Closing Meeting
• Provide a summary of the compliance of site to the Annex and the severity of nonconformities,
• Conclusion as to conformance to Excipient GMP and or GDP shall be stated as the opinion of the audit team.
6.6 Preparing, approving and distributing the audit report

6.6.1 Preparing the audit report
• The audit report shall clearly describe the scope of activities covered by the audit including excipients and grades as well as operational activities.
• The audit report shall disclose any areas of excipient GMP and/or GDP scope that were not covered.

6.6.2 Approving and distributing the audit report
• The audit report shall be reviewed and approved by the Certification Body so that a decision on certification can be made (See Conformity Assessment Section 9.2.5),
• The auditee should have an opportunity to review the draft report for the accuracy of the report contents and to identify the presence of confidential information that may be unnecessary to support the observations. The Auditor shall review any amendments to ensure that the amendments do not detract from the substance of the report,
• Where necessary, the auditee shall be requested to provide a Corrective and Preventive Action (CAPA) plan.

6.7 Completing the audit
• The auditee and the Certification Body shall agree to the disclosure the audit report and any associated CAPA plan to parties approved by the auditee.

6.8 Conducting audit follow-up
The auditee shall be requested to confirm the CAPA plan has been implemented. The status of the CAPAs shall be verified no later than the next audit.
The auditee shall be requested to submit evidence of closure where Critical or Major audit findings are recorded.
7 Competence and Evaluation of Auditors

7.1 General
This flow diagram illustrates the process for identifying, training and evaluating auditors as well as confirmation of their competence.
Auditor competency is a mixture of knowledge, education, training, experience and skill. The interrelationship of these attributes in relation to assessing organizations against the GMP /GDP requirements of EXCiPACT™ is indicated in the following diagram:

### 7.2 Personal Attributes (refer to Appendix A for further details)
Auditors shall be selected based on a number of important personal attributes which shall enable them to be effective. Such effectiveness shall be periodically reviewed relative to these attributes:

- **j) Maturity**
- **k) Sound Judgement**
- **l) Integrity**
- **m) Proven ability to put people at ease and understand the auditee’s perspective.**
- **n) Proven ability to assure conduct of the audit to the audit schedule and within the scope.**

### 7.3 Knowledge and Skills

#### 7.3.1 Generic Knowledge and Skills of Quality Management System Auditors
Auditors shall demonstrate the ability to apply a breadth of knowledge and skills which will enable them to be effective in respect of,

- **a) Audit principles for both GMP and GDP that ensure audits are conducted in a consistent manner.**
  - Seeking agreement with the excipient supplier to audit findings and conclusions,
• Effectively analysing root cause analysis and resulting corrective/preventative action.

b) Knowledge of management system definitions, industry guidance and relevant legislation for auditors of GMP,

• Understanding the application of excipient GMPs to different excipient production processes,
  a. Functionality and dosage forms,
  b. Differing operations to produce the excipient ranging from mineral extraction and purification to chemical or biochemical synthesis,

• Applying the excipient GMP audit guide to different situations,
• Assessing the adequacy of information systems and technology in support of GMP operations (proper use and control of computer systems (e.g. GAMP 5, EU Annex 11, and 21CFR Part 11).

• An understanding of the following:
  a. FDA Guidance on Validation, EU Annex 15,
  b. Basic microbiology and chemistry (to be applied to starting materials prior to introduction to excipient manufacture),
  c. Appropriate Pharmacopoeias,
  d. Cleaning principles as applied to manufacturing process,
  e. IPEC-PQG Excipient GMPs,
  f. Regulations in the intended market (e.g. TSE, Residual Solvents),
  g. Risk assessment techniques (ICH Q9, HACCP, etc.)

• Regulatory requirements for the excipient in the markets sold.

C) Knowledge of management system definitions, industry guidance and relevant legislation for auditors of GDP

• Understanding of different operations of distributors related to distribution and trade of excipients:
  a. Operations involving handling of excipients (Note that there may be operations that require GMP as noted in the GDP Annex),
  b. Office-only operations,

• Applying the excipient GDP audit guide to different situations,
• Assessing the adequacy of information systems and technology in support of GDP operations (demonstration of the proper use and control of computer systems),

• An understanding of distribution related safety and quality systems:
  a. Responsible Care and/or Responsible Distribution Programmes,
  b. Distributors assessment systems (e.g. for Europe Safety Quality Assessment Systems European Single Assessment for Chemical Distributors (SQAS ESAD)),

• Regulatory requirements for the excipient in the markets sold.
d) Understanding of organizational arrangements and cultures,
   - General business processes, including those of both the excipient and pharmaceutical industries,
   - Terminology of both the excipient and pharmaceutical industries,
   - Mechanisms used to distribute excipients.

7.3.2 Generic Knowledge and Skills of Audit Team Leaders
Audit team leaders shall demonstrate the ability to apply a breadth of additional knowledge and skills in addition to the requirements for generic knowledge and skills for auditors (7.3.1);
   - Leadership skills can be demonstrated through supervisory experience.

7.3.3 Specific Knowledge and Skills of Quality Management System Auditors
Auditors shall demonstrate the ability to apply a breadth of knowledge and skills in quality related methods and techniques. Knowledge and skills in this area include:
   - Use of Quality management tools (e.g. SPC, FMEA, etc.),
   - Good documentation practices as applied to records,
   - Demonstration of audit ability e.g. ISO 9001 Registered Lead Auditor, IRCA member, or ASQ Certified Lead Auditor.

7.3.4 Specific Knowledge and Skills of Excipient GMP / GDP System Auditors
Excipient GMP system auditors shall have the knowledge and skills in the following areas:

a) Specific terminology for the excipient being audited.

b) Excipient GMP / GDP quality systems as applied by the manufacturer.

c) Basic understanding of the science and technology of excipient manufacture, distributor operations.
   - Experience working in the excipient industry or with auditing excipient manufacturers and distributors.

7.4 Education, Work Experience, Auditor Training and Audit Experience

7.4.1 Auditors
7.4.1.1 GMP Auditors shall have
a) Completed an education sufficient to meet the acquisition of the requirements in 7.2 and 7.3.

b) Scientific Qualification Work experience
   i. Auditing:
      Attended and passed an ISO 9001 or ISO 14001 Certified Lead Auditor course or be an ASQ Certified Quality Auditor,
   ii. Technical, Managerial, and Professional
• Five years minimum in the Quality Unit at pharmaceutical ingredient or pharmaceutical company with responsibilities that include conformance to GMP requirements. Suitable alternative experience is five years minimum experience performing quality system audits of chemical operations to a recognized standard, e.g. ISO 9001, or
• GDP Auditors may qualify as GMP auditors if they have three years minimum in the Quality Unit at pharmaceutical ingredient or pharmaceutical company with responsibilities that include conformance to GMP or GDP requirements. Suitable alternative experience is three years minimum experience performing quality system audits of chemical or distributor operations to a recognized standard, e.g. ISO 9001, and two years’ experience as a GDP Auditor.

c) Excipient GMP Auditor Training
• Refer to Appendix A for guidance.

d) Excipient Auditor Proficiency
  i. Satisfactory assessment from oral examination of the content of the study guide and practical assessment of a simulated audit of an excipient manufacturer,
  
  ii. Have successfully completed and supervised one audit to demonstrate:
      • Audit skills,
      • Knowledge of excipient GMP conformance requirements,
      • Preparation of audit reports,
      • Appropriate rating of findings,
      • The Certification Body shall witness and assess their auditors on a periodic basis to ensure that they are maintaining standards. (e.g. Experienced Auditor, one supervised audit within three years to successfully demonstrate audit skills or other suitable assessment technique approved by EXCiPACT™).

7.4.1.2 GDP Auditors shall have:
  a) Completed an education sufficient to meet the acquisition of the requirements in 7.2 and 7.3.
  
  b) Scientific Qualification Work experience
      i. Auditing,
         Attended and passed an ISO 9001 or ISO 14001 Certified Lead Auditor course or be an ASQ Certified Quality Auditor,
      ii. Technical, Managerial, and Professional
         • Three years minimum in the Quality Unit at pharmaceutical ingredient or pharmaceutical company with responsibilities that include conformance to GMP or GDP requirements. Suitable alternative experience is three years minimum experience performing quality system audit of chemical or distributor operations to a recognized standard, e.g. ISO 9001.
c) Excipient GDP Auditor Training
   - Two days training covering all relevant excipient GDP principles and processes as described in IPEC GDP Guide and related documents plus applicable sections of the IPEC-PQG Excipient Guide.

d) Excipient Auditor Proficiency
   i. Satisfactory assessment from oral examination of the content of the study guide and practical assessment of a simulated audit of an excipient distributor,
   ii. Have successfully completed and supervised one audit to demonstrate:
      - Audit skills,
      - Knowledge of excipient GDP conformance requirements,
      - Preparation of audit reports,
      - Appropriate rating of findings,
      - The Certification Body shall witness and assess its auditors on a periodic basis to ensure that they are maintaining standards. (e.g. Experienced Auditor, one supervised audit within three years to successfully demonstrate audit skills or other suitable assessment technique approved by EXCiPACT™).

7.4.2 Audit Team Leaders
Demonstrated audit knowledge and skills as described in 7.3.2 and 7.4.1 and confirmed under supervision of a qualified Audit Team Leader and be able to lead and manage an audit team effectively:

7.4.3 Auditors who audit both quality and environmental management systems
Not applicable to EXCiPACT™.

7.4.4 Levels of Education, Work Experience, Auditor Training and Audit Experience
a) Auditor for both GMP and GDP

<table>
<thead>
<tr>
<th>Education 7.4.1.1.a)</th>
<th>Auditor</th>
<th>Audit Team Leader</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tertiary Scientific Qualification</td>
<td>Tertiary Scientific Qualification</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Relevant Audit Experience 7.4.1.1.b) i</th>
<th>Auditor Training in GMP/GDP (knowledge &amp; skills)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 audits prior 2 years</td>
<td>14 contact hours</td>
</tr>
<tr>
<td>5 GMP audits as Audit Team Leader prior 2 years</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total Work Experience 7.4.1.1.b) ii</th>
<th>Auditor Training in GMP/GDP (knowledge &amp; skills)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 years</td>
<td>14 contact hours</td>
</tr>
<tr>
<td>5 years general supervisory experience (7.3.2)</td>
<td></td>
</tr>
</tbody>
</table>
### Auditor training in Excipients

<table>
<thead>
<tr>
<th>Requirements</th>
<th>Contact Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Auditor training in Excipients</td>
<td>7 contact hours</td>
</tr>
<tr>
<td>Auditor training in the ISO 9001 Quality management (ISO9001:2008)</td>
<td>14 contact hours</td>
</tr>
<tr>
<td>Auditor Knowledge Assessment (7.4.1.1. d)ii)</td>
<td>Oral or written exam</td>
</tr>
<tr>
<td>Auditor Assessment (7.4.1.1. d)ii)</td>
<td>Minimum of 1 successful supervised audit</td>
</tr>
</tbody>
</table>

**Note:**

1. Examples of such qualifications are Higher National Diploma (UK), Associates Degree (US.).
2. A successful supervised audit is where the auditor has demonstrated their skills in planning and conducting the audit and documenting the audit.

### Auditor for GDP only

<table>
<thead>
<tr>
<th>Education 7.4.1.2 a)</th>
<th>Tertiary Scientific Qualification1</th>
<th>Tertiary Scientific Qualification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relevant Audit Experience (7.4.1.2 b)ii)</td>
<td>5 audits prior 2 years</td>
<td>3 GDP or GMP audits as Audit Team Leader prior 2 years</td>
</tr>
<tr>
<td>Total Work Experience (7.4.1.2 b)ii)</td>
<td>5 years</td>
<td>5 years general supervisory experience (7.3.2)</td>
</tr>
<tr>
<td>Auditor Training in GDP (knowledge &amp; skills)</td>
<td>14 contact hours</td>
<td>14 contact hours</td>
</tr>
<tr>
<td>Auditor training in the ISO 9001 Quality management (ISO9001:2008 update)</td>
<td>14 contact hours</td>
<td>14 contact hours</td>
</tr>
<tr>
<td>Auditor Knowledge Assessment (7.4.1.2 d)ii)</td>
<td>Oral or written exam</td>
<td>Oral or written exam</td>
</tr>
<tr>
<td>Auditor Assessment (7.4.1.2 d)ii)</td>
<td>Minimum of 1 successful supervised audit</td>
<td>Minimum of 1 successful supervised audit</td>
</tr>
</tbody>
</table>

**Note:**

1. Examples of such qualifications are Higher National Diploma (UK), Associates Degree (US.).
2. A successful supervised audit is one in which the auditor has demonstrated their skills in planning and conducting the audit and documenting the audit report.
7.5 **Maintenance and Improvement of Competence**
Auditors and Audit Team Leaders shall achieve this by:

7.5.1 **Continual Professional Development**
- Attend an annual meeting with EXCiPACT™ Certification Body management to review changes to the programme and programme requirements,
- Attend organizational meetings relevant to excipient GMP and/or GDP,
- Attend organizational meetings relevant to excipient manufacturing and distribution technology and processes.

7.5.2 **Maintenance of Auditing Ability**
- Minimum of one audit per year covering excipient GMP or of excipient GDP.

7.6 **Auditor Evaluation**
Auditors and Audit Team Leaders shall be evaluated on at least a biannual basis (i.e. minimum every 2 years):

7.6.1 **General**
- A documented evaluation that Auditors and Audit Team Leaders continue to have required skills, comprising:
  - A review of audit reports
    - As audit Team Leader,
  - An observation of audit skills,
    - As reported for Auditors by Audit Team Leader,
    - As reported by a management representative who witnessed an audit to observe the Audit Team Leader.

7.6.2 **Evaluation Process**
- An annual records review:
  - Analysis of new records of further education, training, employment and excipient GMP / GDP audit experience since the last review
- Feedback
  - Surveys, questionnaires, complaints, etc. from applicants and others,
  - Audit Team Leader feedback on team participants,
- Interview,
  - Face to face interview,
- Observation,
  - Witnessed audits *for Audit team leader every three years*,
- Maintenance of credentials,
  - Certifications achieved, e.g. ASQ CQA, IRCA Registered Lead Auditor, or ISO 9001 or ISO 14001 Certified or Registered Lead Auditor,
- Post Audit Review,
  - Review of the audit reports and discussion with audit participants.

The continued acceptance or non-acceptance of the Audit Team Leader or Auditor shall be recorded after these assessments.
Requirements for Auditor Qualification and Auditing Excipient Suppliers: Appendix

Section 1 General

1.1 Auditor Roles
In order to manage the complexities of excipient audits and the roles of team members involved, two auditor roles have been established.

- Auditor (including experienced GMP/GDP auditor),
- Audit team leader.

These two roles are differentiated by the extent of the responsibilities assigned to each grade and the potential line management responsibilities that are commensurate with the Audit Team leader grade.

Auditors and audit team leaders will require shared initial foundation experience and knowledge, whereas the audit team leader will require additional skills in areas such as experience in excipient auditing and team management.

1.2 Attaining role status
In order to achieve the role of auditor or audit team leader it is necessary to demonstrate evidence of knowledge and experience.

1.3 Qualifications and Experience
The attributes detailed within the Study Guide (section 2) are considered as they set a minimum knowledge and experience requirement without which the auditor or audit team leader is unsuitable. The study Guide is designed to clearly highlight the expected skills for each grade of auditor.

Professional experience and work based experience is an important element in assessing the suitability of candidates for the position of auditor and audit team leader.

Experience can be demonstrated through a combination of specific audit training evidence and practical application of the original training.

There is a particular requirement to gain expertise in excipient auditing which can be achieved as stated below.

In certain situations there may be more than one way in which an applicant may be successful.

Section 2 Study Guide - Professional/Work Based Experience and Training

Education (7.4.1.a)

Education requirements for Auditor and Audit Team Leader

- Tertiary Scientific Qualification - Examples of such qualifications are Higher National Diploma (UK), Associates Degree (US).

Relevant Audit Experience (7.4.1.bi)

Experience requirements are defined below. The applicant shall be able to demonstrate/show evidence of the content and scope of the audits performed and the applicant’s involvement in the audits:
• Auditor – five audits prior two years. These audits must be in relation to ISO 9001 and/or ISO 14001.
• Experienced GMP/GDP auditor - five GMP audits prior two years. These audits must be in relation to FDA and EU GMPs.
• Audit Team Leader - five GMP audits as Audit Team Leader prior two years.

**Quality Management**
This is applicable to both auditors and audit team leaders.

Candidate auditors shall be able to demonstrate:-

• The knowledge and skills, as defined in 7.3.1 and 7.3.3, to include:
  - Audit principles,
  - Knowledge of management system definitions, industry guidance and relevant legislation,
  - Understanding of organizational arrangements and cultures,
  - Knowledge and skills to understand the regulatory context with respect to: Processes and Products, including services.

This may be achieved primarily through experience as a GMP auditor or ISO 9001, ISO 14001 Registered Lead Auditor.

Candidate Audit Team Leaders shall be able to demonstrate:-

• The additional knowledge and skills as defined in 7.3.2,
• Adequate experience in excipient GMP and GDP auditing.

**GMP**
Candidate auditors shall be able to demonstrate the following knowledge and skills:

• **GMP knowledge and Skills**
  - Knowledge of the GMP excipient guides, primarily the IPEC/PQG guide and other relevant guidelines,
  - Capable of evaluating the interaction between various departments to assure conformance,
  - Capable of assessing the adequacy of information systems and technology in support of GMP operations (proper use and control of computer systems i.e. GAMP, EU Annex 11, and 21CFR Part 11),
  - An understanding (demonstrated by education, experience, or qualifications) in the following areas:
    - FDA Guidance on Validation, EU Annex 15,
    - QMS Risk assessment techniques (ICH Q9, HACCP, etc.),
    - Employee Training in GMP principles as appropriate for their position,
  - Processes and Products, including services: Knowledge and skills to understand the regulatory context of:
    a) Excipient and pharmaceutical industry terminology,
    b) Impact of Technical characteristics of processes on products,
    c) Services typically provided.
Requirements for Auditor Qualification & Auditing of Excipient Suppliers

**GDP**
Candidate auditors shall be able to demonstrate knowledge of the entire content of the IPEC GDP Guide for Pharmaceutical Excipients.

**Excipients**
Candidate auditors shall be able to demonstrate the following knowledge and skills:

- Excipient specific knowledge and skills
  - Understanding the application of excipient GMPs to different excipient production processes, with respect to:
    - Functionality and dosage forms of the end use,
    - Differing operations to produce the excipient ranging from mineral extraction and purification to chemical or biochemical synthesis (for example).
  - Basic microbiology:
    - as applicable to starting materials prior to introduction to excipient manufacture and throughout the manufacturing process,
    - with respect to microbiological quality of water use within the process.
  - Basic chemistry, as applicable to starting materials prior to introduction to excipient manufacture and throughout the manufacturing process.
  - Appropriate Pharmacopoeias.
  - Cleaning principles as applied to manufacturing process.
  - IPEC-PQG Excipient GMPs and GDPs and references as appropriate.
  - Regulations in the intended market (e.g., TSE, Residual Solvents)
  - Organizational Situations:
    - Distribution of excipients and appropriate regulations.
    - Business processes of both excipient and pharmaceutical industries.
    - GMP requirements for the excipient in the markets sold.
  - Processes and Products, including services: Knowledge and skills to understand the regulatory context of:
    - Technical characteristics of the processes and products being audited, including services typically provided.
    - Specific terminology for the excipient being audited.
    - Excipient GMP quality systems as applied by the manufacturer.
    - Basic understanding of the science and technology of excipient manufacture:
      - Experience working in the excipient industry or with auditing excipient manufacturers.
      - Continuing education appropriate to the excipient.
Personal Attributes (7.2)
Attributes desired are:

a) Ethical - must acknowledge the potential for bias or conflict of interest.
b) Open minded - excipient industry is quite diverse in their operations.
c) Diplomatic - avoid being drawn into the role of consultant in the discussion of audit findings with the auditee.
d) Observant - particular emphasis on the possibility for contamination of the excipient

“All auditors need to be able to gather audit evidence. In excipient GMP auditing much evidence can be gathered using the senses. It requires an inquisitive stance and the desire to find out what is actually happening. Auditors will also need to be able to engage in a wide range of topics and ask all manner of questions. It is important to stay focused and not to become side-tracked by areas that are not directly relevant to the audit. Have the instinct to associate observations with the overall perception of the site leading to objective evaluation and further investigation.

e) Perceptive

“be able to work out an understanding of the cause and effect linkages within the auditee’s management system”.

f) Versatile - ability to interpret the standard to the situation e.g. no smoking also would preclude no chewing of tobacco,

g) Tenacious - maintain integrity to the audit and the standard with critical points e.g. no eating or smoking where inappropriate,

h) Decisive,
i) Self-reliant,
j) Personal Development - be supportive of the need for continuing development,
k) Maturity,
l) Sound Judgement,
m) Integrity,
n) Proven ability to put people at ease and understand the auditee’s perspective,
o) Proven ability to assure conduct of the audit to the audit schedule and within the scope.

Total Work Experience
See 7.4.1.bii and 7.4.4

Auditor training in GMP/GDP (knowledge and skills)
The applicant must be able to demonstrate seven contact hours training in core knowledge points, to include but not limited to:

- Equipment qualification and validation (scientific techniques used
to demonstrate a state of control e.g. validation, Statistical process Control, Design of Experiments),

- Pharmacopeia and laboratory requirements for QC testing,
- Cleaning principles as applied to manufacturing process,
- ½ hour education on “Where excipient GMP begins”,
  - ½ hour training on assessment or review of risk based on route of administration,
- 1 hour audit report writing and rating findings.

**Auditor training in excipients (7.4.1.1.c)**

The applicant must be able to demonstrate seven contact hours training in excipient GMP conformance requirements, to include but not limited to:

- Contamination control - particular attention must be paid where the excipient can become contaminated,
- Review of starting point for excipient GMP,
  - Review of additional GMP expectations for assessment or review of risk based on route of administration,
- 1 hour overview of the Excipient GMP certification program,
  - Include conflict of interest,
  - Confidentiality.

**Auditor training in GDP (knowledge and skills) (7.4.1.2.c)**

The applicant must be able to demonstrate 7 contact hours training in core knowledge points as included in the IPEC GDP Guide for Pharmaceutical Excipients:

- Quality Management,
- Organization and Personnel,
- Premises,
- Warehousing and Storage,
- Equipment,
- Documentation,
- Repackaging and Relabelling,
- Complaints,
- Recalls,
- Returned goods,
- Handling of non-conforming materials,
- Dispatch and Transport,
- Contract activities.

**Auditor training in the ISO 9001 Quality management (ISO9001:2008 update)**

14 Contact hours
Conformity Assessment Requirements for Certification Bodies: Foreword

Certification of a quality management system provides independent confirmation that the management system of the organization:

a) Conforms to specified requirements,

b) Is capable of consistently achieving its stated policy and objectives,

c) Is effectively implemented, and

d) Regularly assessed.

This part of EXCiPACT™ provides generic requirements for certification bodies performing audit and certification in the field of an excipient GMP and GDP quality management system. Such bodies are referred to as Certification Bodies. Certification activities involve the audit of an organization’s quality management system.

This document is an Annex to ISO/IEC 17021:2006, Conformity assessment requirements for bodies providing audit and certification of management systems, as this is the most appropriate publicly available document commonly used by 3rd party audit organizations. The headings and sections in this document are those of ISO/IEC 17021:2006 and any additional text stipulates requirements to be implemented together with the ISO/IEC 17021:2006 clauses in order to perform EXCiPACT™ GMP and GDP certification assessments.

Where a heading or section of ISO/IEC 17021:2006 is omitted then there are no additional requirements to those already stipulated in ISO/IEC 17021:2006.

Thus the requirements in this document will be simple to implement in organizations that are already using the ISO/IEC 17021:2006 as the basis of their auditing and for defining auditor competency.

The main text that follows is based on the headings in ISO/IEC 17021:2006 and the details are the EXCiPACT™ requirements:

**Text in Bold are ISO/IEC 17021:2006 Headings**

**Standard Text are EXCiPACT™ requirements.**

*Italicised text is from ISO/IEC 17021:2006*
1 Scope
The standard contains the principles and requirements for the quality management system operated by EXCiPACT™ certification bodies. The requirements assure the impartiality, competence and consistency of EXCiPACT™ audits and the certification of the quality management systems of Excipient suppliers.

2 Normative References
ISO/IEC 17021:2006: Conformity assessment – Requirements for bodies providing audit and certification of management systems.

3 Terms and definitions
Auditee: The excipient supplier being assessed.
Certified auditee: Organization whose quality management system has been certified to EXCiPACT™.

4 Principles
4.1 Principles that inspire confidence include:
No additional requirements.

4.2 Impartiality
It is essential that 3rd party audit organizations base decisions on objective evidence collected at audit, from which they can judge conformity or non-conformity to the EXCiPACT™ GMP and/or GDP requirements. Such decisions shall not be influenced by other interests or other parties.

4.3 Competence
The requirements for auditor competency set out in the EXCiPACT™ section dealing with the requirements for auditor competency shall be met.

4.4 Responsibility
The auditee has the responsibility for conformance to the ISO 9001:2008 and EXCiPACT™ GMP or GDP certification requirements.

The certification body has responsibility to assess the auditee against ISO 9001:2008 and EXCiPACT™ GMP and/or GDP requirements.

4.5 Openness
No additional requirements.

4.6 Confidentiality
Non-public information gathered as part of the audit process shall not be disclosed to other parties without the permission of the auditee.

4.7 Responsiveness to complaints
No additional requirements.

5 General requirements
5.1 Legal and contractual matters
5.1.1. Legal responsibility:
No additional requirements.
5.1.2. **Certification agreement:**
No additional requirements.

5.1.3. **Responsibility for certification decisions:**
No additional requirements.

5.2. **Management of impartiality**

5.2.1. The 3rd party audit organization shall make publically available a statement that indicates it understands the criticality of impartiality in carrying out GMP and / or GDP certification assessments, that it manages conflicts of interest and ensures the objectivity of its certification activities.

5.2.2. The 3rd party audit organization shall have a documented risk assessment that evaluates threats that could result in conflicts of interests arising from certification activities and the attendant relationships. No individual shall be involved in the certification process if they provide consultation on excipient GMP conformance to the auditee (see 5.2.5).

5.2.3. No additional requirements.

5.2.4. No additional requirements.

5.2.5. The certification body or any auditor (including ex-employees or consultants) shall not provide management system, GMP or GDP consulting within two years of the completion of any certification of the auditee.

5.2.6. No additional requirements.

5.2.7. No additional requirements.

5.2.8. No additional requirements.

5.2.9. No additional requirements.

5.2.10. To ensure that there is no conflict of interests, the certification body or any auditor (including ex-employees or consultants) who have provided management system, GMP or GDP consultancy shall not participate in any audit or certification activities of the organization within two years following the end of the consultancy.

5.2.11. No additional requirements.

5.2.12. No additional requirements.

5.2.13. All personnel associated with certification shall be required to notify top management of the certification body of any threats or potential threats to impartiality.

5.3. **Liability and financing**
No additional requirements.

6. **Structural requirements**

6.1. **Organizational structure and top management**

6.1.1. No additional requirements.

6.1.2. *The certification body shall identify the top management (board, group or persons, or person) having overall authority and responsibility for the following:*

j) Oversight of the appeals process.
6.1.3. No additional requirements.

6.2. Committee for safeguarding impartiality
6.2.1. No additional requirements:

6.2.2. If top management does not respect the advice of the committee, the committee shall have the authority to inform EXCiPACT™.

6.2.3. No additional requirements.

7 Resource Requirements

7.1. Competence of management and personnel
7.1.1. The certification body shall have processes to ensure that personnel have appropriate knowledge in GMP and/or GDP management systems. The competence requirements shall be established and annually demonstrated to EXCiPACT™ in accordance with the auditor competency section of EXCiPACT™ (see also 7.2.10).

7.1.2. No additional requirements.

7.1.3. The certification body shall have access to the necessary technical expertise on excipient regulations, GMP and/or GDP within the geographic areas they operate.

7.2. Personnel involved in the certification activities
7.2.1. No additional requirements.

7.2.2. No additional requirements.

7.2.3. No additional requirements.

7.2.4. The certification body shall designate a qualified auditor to act as supervisor in the qualification of auditors. The supervisor shall be a Lead Auditor in the programme and display appropriate skills to supervise candidate auditors.

7.2.5. The certification body shall demonstrate effective auditing in conformance to the EXCiPACT™ auditor competency requirements.

7.2.6. No additional requirements.

7.2.7. Auditors and technical experts shall only be used for certification activities where they have demonstrated competence as stipulated in EXCiPACT™ Auditor Competency Requirements.

7.2.8. The certification body shall identify on-going training needs and provide access to training for all personnel in accordance with EXCiPACT™ Auditor Competency Requirements.

7.2.9. Those individuals, who are responsible for the decision to grant, maintain, renew, extend, reduce, suspend or withdraw an EXCiPACT™ GMP and/or GDP certificate shall understand the EXCiPACT™ GMP and/or EXCiPACT™ GDP standards and certification requirements. The technical experts shall be independent and free from conflict of interest of the audit process they are to review. The technical experts shall have proven knowledge and experience in the pharmaceutical and/or excipient industry.
7.2.10. There shall be annual performance evaluation of those involved in the certification programme plus assessment of audit skills every 3 years. Competence evaluations shall lead to identification of training needs.

7.2.11. Monitoring of auditor performance includes a combination of on-site observation, review of audit reports and feedback from auditees or the market (regulators, pharmaceutical makers) in accordance with ISO 19011:2002 Section 7.4.1d) and the corresponding section in the EXCiPACT™ Auditor Competency Requirements.

7.2.12. There shall be periodic on-site observation of auditor performance not to exceed 3 years in accordance with EXCiPACT™ Auditor Competency Requirements.

7.2.13. The certification body shall notify EXCiPACT™ of the names of all auditors qualified to perform EXCiPACT™ certification audits.

7.3. **Use of individual external auditors and external technical experts**

No additional requirements.

7.4. **Personnel records**

No additional requirements.

7.5. **Outsourcing**

The certification body shall not delegate responsibility for certification to another organization. Where it requires additional resources to perform certification activities those resources shall satisfy the requirements in this Annex (see 7.2, 7.3, 7.4).

The certification body shall have documented procedures for qualification and monitoring of outsourced services.

8. **Information requirements**

8.1. **Publicly accessible information**

8.1.1. Information describing the audit and certification process for granting, maintaining, extending, renewing, reducing, suspending, or withdrawing certification shall be publicly accessible through EXCiPACT™.

8.1.2. No additional requirements,

8.1.3. Certifications granted, suspended, or withdrawn must be reported to EXCiPACT™ who will make such information publicly available.

8.1.4. The certification organization shall provide the means to validate a given certification, and the associated audit reports.

8.2. **Certification Documents**

No additional requirements.

8.3. **Directory of certified auditees**

EXCiPACT™ shall maintain a directory of valid certifications, including the name, standard, scope and geographical location, for each certified auditee.
8.4. **Reference to certification and use of marks**

8.4.1. **EXCiPACT™ requirements for certification include:**

1) **EXCiPACT™** will issue a unique number for each certificate issued by the certification body. This number is to be used as a component of the Certified Excipient Mark.

2) Certified Organizations are entitled to use the Certified Excipient Mark on letter headings, business cards, brochures, advertisements and other promotional material including vehicles. The Mark may also be used on outer packaging, trade samples and flags.

3) The Certified Excipient Mark may be reproduced in any size but shall not be displayed where the resulting printed definition becomes unclear or the text (including a unique number whose prefix identifies the certification body that granted certification) becomes unreadable to the naked eye.

4) The Mark must be reproduced in its entirety, including the surrounding outline.

5) The Mark may be reproduced in any colour.

6) The Certified Excipient Mark must not be used on, or closely associated with, products in such a way as to imply that the product itself is certified.

7) The company is required by contract to use the mark as required by **EXCiPACT™**.

8.4.2. The mark may only be applied to the Certificate of Analysis where the mark is displayed as part of the document letterhead and does not convey the impression that certification includes verification of excipient quality.

8.4.3. **The certification body shall require that the auditee organization:**

f) Does not allow reference to certification to imply certification of the excipient.

8.4.4. The certification body exercises control of ownership and takes action to deal with incorrect references to certification status or misleading use of certification documents, marks, or audit reports. The certification body shall notify the excipient certification programme owner of any such incidents.

8.5. **Confidentiality**

No additional requirements.

8.6. **Information exchange between a certification body and its auditees**

8.6.1. **Information on the certification activity and requirements**

No additional requirements

8.6.2. **Notice of changes by a certification body**

Upon receipt of changes from **EXCiPACT™**, an implementation plan shall be
developed by the certification body which comprises the following:

- Description of the change to the Certification Programme,
- Potential impact of the change to the auditees,
- Timeframe within which the applicants are to implement the change,
- Verification schedule that the change by applicants has been completed.

There shall be

- A prompt verification of programme changes,
- A review of confirmatory documentation, or
- On-site verification at the next scheduled site audit that changes have been implemented,
- Establishment of a future effective date by which all applicants must comply with the new requirements, otherwise their right to issue EXCiPACT™ certificates is suspended.

8.6.3. Notice of changes by an auditee
No additional requirements.

9 Process Requirements

9.1. General Requirements

9.1.1. There shall be a two-stage initial audit, surveillance audits (at least annually) at which aspects of the GMP and / or GDP Annex will be assessed. Every third year there shall be a complete audit report covering the GMP and / or GDP Annex for review by the technical experts who recommend recertification. The duration of audits shall be adjusted according to the scope and complexity of the GMP / GDP system and excipients produced.

9.1.2. No additional requirements.

9.1.3. Additional requirements.

- Where the audit is conducted to certify conformance with ISO 9001:2008 plus the GMP/GDP Annex, the audit team shall include an ISO 9001 Registered Lead Auditor.
- Where the audit is conducted solely to the GMP/GDP Annex, the audit team does not require an ISO 9001 Registered Lead Auditor.

9.1.4. The time allotted for the audit shall be adequate to assess conformance to excipient GMP / GDP requirements in addition to any time required for any concurrent ISO 9001:2008 assessment. In determining the time required the following shall be considered,

- The number of excipients manufactured at a location, and the differences in chemistry used to prepare them,
- The complexity of the technology and the management systems used to manufacture the excipients,
- Any other activities within the scope of the certification,
- The number of sites on which the activities occur that are within the scope of the audit.
The following is provided as a guide only for planning adequate time to assess the site:

<table>
<thead>
<tr>
<th>Complexity</th>
<th>Initial assessment (auditor days)</th>
<th>Annual surveillance visits (auditor days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment scenario</td>
<td>Total</td>
<td>On-site</td>
</tr>
<tr>
<td>1. Single Excipient / Simple arrangements</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>2. Multiple grades &lt;&gt; chemistry</td>
<td>6.5</td>
<td>5</td>
</tr>
<tr>
<td>3. Multiple grades, &lt;&gt; equipment</td>
<td>6.5</td>
<td>5</td>
</tr>
<tr>
<td>4. Multiple excipients</td>
<td>7.5</td>
<td>6</td>
</tr>
</tbody>
</table>

Additional Time for:

1. Off-site operations                           | 0.25-0.5 | 0.25-0.5 | 0.25-0.5 | 0.25-0.5
2. Complex operations                            | 0.25-0.5  | ≥0.25    | 0.25-0.5  | ≥0.25

9.1.5. The Certification Body shall audit all sites that produce the excipient at initial certification. Once evidence is in place to demonstrate the Quality Management Systems at each of the sites are the same, then further surveillance and re-assessment audits can be performed on a risk based frequency. This risk assessment shall consider the known use and application of the products made at those sites with higher frequencies required where the excipient use poses higher potential risks to patients.

9.1.6. No additional requirements.

9.1.7. No additional requirements.

9.1.8. No additional requirements.

9.1.9. No additional requirements.

9.1.10. The audit report shall contain sufficient information and detail to allow the certification board to accurately assess the compliance of the auditee against the EXCiPACT™ GMP and or GDP requirements and include:
   - Name of the company,
   - Location of the site audited,
   - Dates of the site audit,
   - Names and qualifications of audit team members,
   - Scope of operational activities covered by the audit,
   - Name of the excipient(s) audited including both monograph and trade names, and
     i. Objective evidence for each section audited,
     ii. Reference to the clause for each observation above,
   - Rating for each observation: acceptable, critical, major, or minor.

---

6 Surveillance audit may be conducted only once during the recertification interval.
9.1.11. The auditee shall be required to provide root cause analysis and corrective measures within a prescribed timeframe.

- Applicants shall be given an opportunity to correct findings and the draft audit report for errors or omissions.
- Implementation of appropriate preventive or corrective measures shall be confirmed.
  i. If a finding can be remedied while the audit is progressing, the corrective measure shall be noted in the audit report.
  ii. If a finding can be remedied prior to the decision on certification the audit report shall updated to include the remediation so that consideration can be given to the decision on certification.
  iii. If certification is granted contingent upon the implementation of stated corrective or preventive measures, completion by their due date shall be verified by the Certification Body through appropriate means, e.g. document review, site visit, etc. and the audit report shall be updated.
- The auditee shall be encouraged to submit a corrective action plan. The plan, if provided, shall be included with the audit report for review under 10.2.5.1.

9.1.12. The Certification Body shall ensure at least one auditor (ideally the audit team leader) who performed the assessment of the auditee has determined the adequacy of corrective measures.

9.1.13. No additional requirements.

9.1.14. No additional requirements.

9.1.15. *The Certification Body shall confirm, prior to making a decision, that:*

- The audit report contains sufficient information
- The corrective measures have been reviewed, accepted, and verified for effectiveness for all nonconformities that represent:
  i. Failure to fulfil one or more requirements of GMP / GDP, or
  ii. Raise significant doubt about conformance of the quality system to GMP / GDP.

9.2. **Initial Audit and Certification**

9.2.1. **Application**

No additional requirements.

9.2.2. **Application review**

9.2.2.1. *Before proceeding with the audit, the certification body shall conduct a review of the application and supplementary information for certification to ensure that:*

  g) the certification is for excipient GMP and or Excipient GDP,
  h) safety issues have been identified

9.2.2.2. No additional requirements.

9.2.2.3. No additional requirements.
9.2.2.4. No additional requirements.

9.2.3. Initial certification audit

9.2.3.1. Stage 1 audit

9.2.3.1.1. The Stage 1 audit is performed to assess the auditee’s Quality Management System and discuss preparation for the Stage 2 audit.

Note: the Stage 1 audit can be used to determine the duration of the Stage 2 audit.

9.2.3.1.2. No additional requirements

9.2.3.1.3. No additional requirements.

9.2.3.2. Stage 2 audit

The Stage 2 audit is to evaluate implementation and effectiveness of the management system and includes:

- Information and evidence of conformity to excipient GMPs / GDPs,
- Links between normative requirements, policy, performance objectives, and targets consistent with the expectations of excipient GMPs / GDPs, any regulatory requirements, responsibilities, competence of personnel, operations, procedures, performance data, and internal audit findings and conclusions.

9.2.4. Initial certification audit conclusions

No additional requirements.

9.2.5. Information for granting initial certification

Non-conformances or findings shall be classified as Life Threatening, Critical, Major, or Minor

**Life Threatening:** A nonconformity or other situation which has produced a product that is harmful to the human or veterinary patient, or one which poses a very high risk of producing product that is harmful to the human or veterinary patient.

**Critical:** The excipient poses significant risk to patient safety. Remediation before further excipient is produced would be indicated and/or a recall should be considered.

**Major:** Evidence indicates that the Quality Management System is not effectively developed or implemented. For instance, the system is poorly designed or not followed; or multiple or repetitive minor nonconformities in the same aspect of the quality management system, and or evidence that the product consistently fails to meet the requirements for use as an excipient.

**Minor:** A departure from the standard that is neither a critical nor major. Action to rectify the finding is indicated.

For Certification the acceptance criteria are:

1. No items rated as Life Threatening
2. No items rated as Critical.
3. No items rated as Major.

For continuing Certification, the Surveillance audit shall have:
1. No items rated as Critical.
2. No items rated as Major unless the deficiency has been remediated or an interim control is in-place i.e. CAPA plan accepted by the Certification Body and verified.
3. No items rated as Minor from a prior audit that have either not been corrected or for which an acceptable CAPA plan has not been developed.

9.2.5.1. No additional requirements.
9.2.5.2. No additional requirements.

9.2.6. Issuing certification and audit reports

9.2.6.1 Following a positive assessment, the certification body shall provide the auditee with an EXCiPACT™ Certificate. This shall contain the following as a minimum:
- The name of the auditee
- The address of each certified location
- The initial date of certification
- The date of the latest recertification
- A statement indicating if certification has been continually held between the initial date and the latest certification date
- The date of recertification (if applicable)
- A clearly defined scope of the assessment at each location, including details of the product ranges manufactured or distributed at those locations.

9.2.6.2 The Certification Body shall provide a means of authenticating EXCiPACT™ certificates to 3rd parties who may require confirmation of their validity.

9.2.6.3 The Certification Body shall provide an audit report to the auditee for each certification and surveillance audit.

9.2.6.4 On request of the auditee, the Certification Body shall prepare a copy of the audit report which has been redacted to protect confidential information. This information shall only be redacted if it has no impact on the assessment outcomes (e.g. removal of non-conformities or other assessment outcomes). The auditee shall be given permission to permit sharing of redacted audit reports as long as the whole report is issued.

**Note:** the purpose of the redacted version of the audit report is to allow the auditee to issue it to customers as additional assurance of the capability of their quality management system.

9.2.6.5 The Certification Body shall provide an authentication service to those excipient users who require confirmation that the audit report has been prepared by the certification body, and is unaltered from the one originally issued.
9.3. Surveillance activities

9.3.1. General

9.3.1.1. No additional requirements.

9.3.1.2. No additional requirements.

9.3.2. Surveillance audit

9.3.2.1. No additional requirements:

9.3.2.2. Surveillance audits are conducted at least annually and cover at least half of the quality system such that the entire excipient quality system will be reviewed by the two surveillance audits that occur in between recertification audits.

9.3.3. Maintaining certification

No additional requirements.

9.4. Recertification

No additional requirements

9.4.1. Recertification audit planning

9.4.1.1. Recertification shall occur at intervals of not more than three years after initial certification or last recertification. The recertification audit shall be planned and conducted to confirm that the requirements of excipient GMP /GDP continue to be met.

9.4.1.2. No additional requirements.

9.4.1.3. No additional requirements.

9.4.1.4. The audit shall assess all sites covered by the certification and be conducted triennially.

9.4.1.5. The same auditor shall not audit the same organization for more than three consecutive audits.

9.4.2. Recertification audit

9.4.2.1. No additional requirements.

9.4.2.2. No additional requirements.

9.4.3. Information for granting recertification

No additional requirements.

9.5. Special audits

9.5.1. Extensions to scope

No additional requirements.

9.5.2. Short-notice audits

No additional requirements.

9.6. Suspending, withdrawing or reducing the scope of certification

9.6.1. No additional requirements.

9.6.2. The certification body shall suspend certification in cases when, for example:

- There have been persistent or serious failures to meet
certification requirements

- A regulatory authority inspection has found significant deviation from GMP / GDP requirements that meets the definition of critical finding (see 9.2.5),

In either of these two cases the Certification Body shall notify EXCiPACT™ immediately of the situation and the reasons for the suspension,

- The auditee has not paid the certification fee within the prescribed period.

9.6.3. Under suspension, the auditee shall refrain from promoting certification. The certification body shall notify EXCiPACT™ of the auditee suspension.

9.6.4. No additional requirements.

9.6.5. No additional requirements.

9.6.6. No additional requirements.

9.6.7. No additional requirements.

9.7. Appeals

9.7.1. No additional requirements.

9.7.2. No additional requirements.

9.7.3. No additional requirements.

9.7.4. No additional requirements.

9.7.5. The appeals handling process shall include at least the following elements and methods:

d) Where the appeal cannot be resolved to the satisfaction of the auditee, the appeal shall be escalated to EXCiPACT™.

9.7.6. No additional requirements.

9.7.7. No additional requirements.

9.7.8. Formal notice shall be given to the petitioner at the closure of the appeal by the Certification Body. If not satisfied, the petitioner can appeal to EXCiPACT™ whose decision is final.

9.8. Complaints

9.8.1. No additional requirements.

9.8.2. No additional requirements.

9.8.3. No additional requirements.

9.8.4. No additional requirements.

9.8.5. No additional requirements.

9.8.6. No additional requirements.

9.8.7. No additional requirements.

9.8.8. No additional requirements.

9.8.9. No additional requirements.

9.8.10. The Certification Body, together with the auditee and complainant,
shall determine the extent to which the complaint and resolution is made public. If not satisfied with the complaint resolution process or decision, the auditee or complainant can raise the matter with EXCiPACT™ whose decision is final.

9.8.11. EXCiPACT™ shall be notified of all complaints received from auditees concerning the EXCiPACT™ certification scheme, and their outcomes.

9.8.12. In exceptional cases EXCiPACT™ may require the Certification Body to cease providing services to the auditee.

9.9. Records of applicants and auditees
9.9.1. No additional requirements.
9.9.2. No additional requirements.
9.9.3. No additional requirements.
9.9.4. No additional requirements.

10 Management system requirements for certification bodies

10.1. Options
The certification body shall have a management system that meets the requirements of clauses 5-9 and ISO Guide 65, ISO Guide 17021 or equivalent.

10.2. Option 1: Management system requirements in accordance with ISO 9001:2008
No additional requirements.

10.3. Option 2: General management system requirements
10.3.1. General
No additional requirements.

10.3.2. Management system manual
No additional requirements.

10.3.3. Control of documents
No additional requirements.

10.3.4. Control of records
No additional requirements.

10.3.5. Management review
No additional requirements.

10.3.6. Internal audits
10.3.6.1. No additional requirements.
10.3.6.2. Audits shall be planned using a risk-based approach to areas covered.
10.3.6.3. No additional requirements.
10.3.6.4. No additional requirements.

10.3.7. Corrective actions
No additional requirements.

10.3.8. Preventive actions
No additional requirements.
Definitions
Terms used in this document, which have a specific technical meaning, are defined here.

1. **acceptance criteria:** Numerical limits, ranges, or other suitable measures of acceptance for test results [Q7]

2. **active pharmaceutical ingredient (API):** Any substance or mixture of substances, intended to be used in the manufacture of a drug product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure or any function of the body of man or animals. [IPEC]

3. **adequate:** Sufficient, although not necessarily the most or the best.

4. **appropriate:** A quality of being just right for the requirements.

5. **audit team leader:** A qualified individual who organizes, coordinates, and is qualified to conduct audits to the GMP or GDP Annexes as applicable.

6. **batch (lot):** A specific quantity of material produced in process or a series of processes so that it can be expected to be homogenous. In the case of a continuous process, a batch may correspond to a defined fraction of the production. The batch size can be defined by a fixed quantity or by the amount produced in a fixed time interval. [IPEC] ANSI NSF reworded to: **batch:** A specific quantity of material produced in a process or a series of processes so that it may be expected to be uniform in character and quality, within specified limits. In the case of a continuous process, a batch may correspond to a defined fraction of the production. The batch size may be defined by a fixed quantity or by the amount produced in a fixed time interval.

7. **batch number (Lot Number):** A unique combination of numbers, letters and/or symbols that identifies a batch (or lot) and from which the production and distribution history can be determined. [Q7]

8. **batch process:** A process that produces the excipient from a discrete supply of raw materials that is present before the completion of the reaction. [Q7]

9. **batch record:** Documents that provide a history of the manufacture of a batch of excipient. [IPEC PQG GMP]

10. **broker / brokering:** Brokers resell excipients without conducting physical handling of the product such as warehousing, transport, repackaging etc.[IPEC GDP]

11. **bulk excipient:** Excipient in any transportation or storage equipment (tanks, silos, ISO-Containers, tank/silo trucks etc.) to be filled/ repackaged into others (tanks, silos, drums, bags, containers etc.).

12. **certificate of analysis (COA):** A document listing the test methods, specification and results of testing a representative sample from the batch to be delivered. [IPEC]

13. **change:** Anything that alters an excipient’s physical, chemical and/or microbiological characteristics from the norm, or that is likely to alter the excipient performance in the dosage form.

14. **change control:** A process used for management review of proposed
changes that may impact the quality or regulatory conformance of the excipient. [IPEC]

15. **competency**: The demonstrated personal attributes and demonstrated ability to apply knowledge and skills. [ISO 19011:2002].

16. **component**: Any material present in the excipient that arises as a consequence of the raw materials and/or manufacturing process. [IPEC]

17. **computer system**: A group of hardware components and associated software, designed and assembled to perform a specific function or group of functions. [IPEC]

18. **contaminant**: An undesired material of a chemical or microbiological nature or foreign matter introduced from a raw material, intermediate, or excipient during production, sampling, packaging, storage or transport. [IPEC]

19. **contamination**: The undesired introduction of impurities of a chemical or microbiological nature or foreign matter into or onto a raw material, intermediate or excipient during production, sampling, packaging or repackaging, storage or transport. [IPEC]

20. **continual improvement**: Recurring activity to increase the ability to fulfil requirements. [IPEC]

21. **continuous process**: A process that continually produces material from a continuing supply of raw material. [IPEC]

22. **contract**: Business agreement for supply of goods or performance of work at a specified price. [WHO GTDP]

23. **corrective action**: Action to eliminate the cause of a detected non-conformity or other undesirable situation. NOTE – Corrective action is taken to prevent recurrence whereas preventive action is taken to prevent occurrence. [IPEC]

24. **critical**: A process step, process condition, test requirement or other relevant parameter or item that must be controlled within predetermined criteria to ensure that the excipient meets its specification. [IPEC]

25. **cross-contamination**: Contamination of a material or product with another material or product. [Q7]

26. **customer**: The organization receiving the excipient once it has left the control of the excipient manufacturer; includes brokers, agents and users. [IPEC]

27. **deviation**: Departure from an approved instruction or established standard. [Q7]

28. **distributor(s)**: For the purpose of this Annex “distributors” includes those parties involved in trade and distribution, (re)processors, (re)packagers, transport and warehousing companies, forwarding agents, brokers, traders, and suppliers other than the original manufacturer.

29. **documented procedure**: A written procedure meeting the requirements of 4.2.3.

30. **drug product**: Dosage form intended for use by a patient.

31. **effectiveness**: An expression of the degree to which activities have produced the effects planned. [IPEC]

32. **excipient**: Substances other than the API which have been appropriately evaluated for safety and are intentionally included in a drug delivery system. [IPEC]
33. **expiry (expiration) date:** The date designating the time during which the excipient is expected to remain within specifications and after which it should not be used. [IPEC].

34. **functionality:** A desirable property of an excipient that aids and/or improves the manufacture, quality, or performance of the drug product. [IPEC]

35. **good distribution practices (GDP):** Requirements for the quality system under which drug products and their ingredients are handled and distributed.

36. **good manufacturing practices (GMP):** Requirements for the quality system under which drug products and their ingredients are manufactured. Current Good Manufacturing Practice (cGMP) is the applicable term in the United States. For the purposes of this guide, the terms GMP and cGMP are equivalent. [IPEC]

37. **ICH:** International Conference on Harmonisation. [IPEC]

38. **IPEC:** International Pharmaceutical Excipients Council. [IPEC]

39. **IPEC PQG:** International Pharmaceutical Excipients Council and the Pharmaceutical Quality Group. [IPEC]

40. **impurity:** An undesirable component of an excipient that is present as a consequence of the raw materials, excipient manufacturing process, or excipient degradation. Impurities are expected to be controlled at a specified level.

41. **in-process control/testing:** Checks performed in production to monitor and, if appropriate, to adjust the process and or to ensure that the intermediate or excipient conforms to its specification. [IPEC PQG GMP]

42. **intermediate:** Material that must undergo further manufacturing steps before it becomes an excipient. [IPEC PQG GMP]

43. **labelling:** The action involving the selection of the correct label, with the required information, followed by line-clearance and application of the label. [WHO GTDP]

44. **justified:** A documented explanation.

45. **lot:** see Batch [IPEC]

46. **manufacture / manufacturing process:** All operations of receipt of materials, production, packaging, repackaging, labelling, relabelling, quality control, release, storage, and distribution of excipients and related controls. [IPEC PQG GMP].

47. **material:** A general term used to denote raw materials (starting materials, reagents, and solvents), process aids, intermediates, excipients and packaging and labelling materials. [Q7]

48. **non-conformance:** A non-fulfilment of requirements.

49. **non-conforming material:** Material that does not meet the manufacturer’s specifications or has not been manufactured according to applicable GMPs [IPEC GDP].

50. **organization:** As in ISO 9001:2008, “organization” is used in this Annex to indicate the entity to which the requirements apply.

51. **original manufacturer:** Person or company manufacturing a material to the stage at which it is designated as a pharmaceutical starting material. [WHO GTDP]
52. **packaging material**: A material intended to protect an intermediate or excipient during storage and transport. [IPEC]

53. **pharmaceutical starting material**: A pharmaceutical starting material is an active pharmaceutical ingredient (API) or an excipient intended or designated for use in the production of a pharmaceutical product. [WHO GTDP]

54. **preventive action**: Action to eliminate the cause of a potential non-conformity or other undesirable potential situation. NOTE – [IPEC] Preventive action is taken to prevent occurrence whereas corrective action is taken to prevent recurrence. [IPEC]

55. **primary reference standard**: A substance that has been shown by an extensive set of analytical tests to be authentic material that is of high purity and to which all like standards are traced and qualified or certified. This standard is preferably obtained from an officially recognized source. If no official recognized source is available, the reference standard selected shall be appropriately characterized.

56. **procedure**: Written, authorized instruction for performing specified operations. (see documented procedure) [IPEC GTDP]

57. **process**: The combination of operating steps including synthesis, isolation, purification, packaging, etc. that produces the finished excipient. [IPEC]

58. **product lifecycle**: All phases in the life of the product from the initial development through marketing until the product’s discontinuation. [IPEC]

59. **product realization**: Achievement of an excipient with the quality attributes appropriate to meet the needs of patients, health care professionals, regulatory authorities, and internal customers’ requirements. [IPEC]

60. **production**: Operations involved in the preparation of an excipient from receipt of materials through processing and packaging of the excipient. [IPEC]

61. **quality**: The suitability of an excipient for its intended use as indicated by relevant physical, chemical, and microbiological properties and as assured by compliance with these standards.

62. **quality assurance**: The sum total of the organised arrangements made with the object of ensuring that all excipients are of the quality required for their intended use and that quality systems are maintained. [IPEC PQG GMP]

63. **quality control (QC)**: Checking or testing that specifications are met. [IPEC]

64. **quality critical**: Describes a material, process step or process condition, test requirement or any other relevant parameter that directly influences the quality attributes of the excipient and which must be controlled within predetermined criteria. [IPEC]

65. **quality management system (QMS)**: A management system that directs and controls how the organization implements quality policies and achieves quality objectives.

66. **quality risk management**: A systematic process for the assessment, control, communication, and review of risks to the quality of the excipient across its lifecycle.

67. **quality system**: See Quality Management System.
68. **quality unit:** An organizational unit independent of production which fulfills both Quality Assurance and Quality Control responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization. [IPEC].

69. **quarantine:** The status of materials isolated physically or by other effective means pending a decision on their subsequent approval or rejection. [IPEC].

70. **raw material:** A general term used to denote starting materials, reagents and solvents intended for use in the production of intermediates or excipients. [IPEC].

71. **recall (USA: . retrieval):** A process for withdrawing or removing a pharmaceutical material from the distribution chain because of defects in the materials or complaints of a serious nature. The recall might be initiated by the manufacturer/importer/distributor or a responsible agency. [WHO GTDP].

72. **record:** Document stating results achieved and/or providing evidence of activities performed. The medium may be paper, magnetic, electronic or optical, photographic etc. or a combination thereof. [IPEC].

73. **relabelling:** The process of putting a new label on the material (see also labelling). [WHO GTDP].

74. **repackaging:** The action of changing the packaging of the material. [WHO GTDP].

75. **representative sample:** A quantity of the excipient taken according to a prescribed rationale so as to accurately portray the material being sampled (e.g. a batch).

76. **reprocessing:** Repetition of an activity that is a normal part of the manufacturing process and that has been documented previously. [IPEC].

77. **requirements:** The explicit or implicit needs or expectations of the governing standards. [IPEC].

78. **resources:** suggested definition: Source of supply, support or aid, especially one that can be readily drawn upon when needed [4.1, bullet d, 5.4.2, 5.6.3.6.1].

79. **retained sample:** Representative sample of a batch/delivery that is sufficient quantity to perform at least two full quality control analyses and will be kept for a defined period of time. [IPEC].

80. **retest date:** The date when a material should be re-examined to ensure that it is still suitable for use. [IPEC].

81. **retest/re-evaluation interval:** The duration, normally expressed in months or years, from the date of manufacture, throughout which the excipient should continue to conform to the specification and after which should be tested to confirm it continues to meet the specification. [IPEC].

82. **reworking:** Subjecting previously processed material that did not conform to standards or specifications to processing steps that differ from the normal process. [IPEC].

83. **risk assessment:** A systematic process of organizing information to support a risk decision to be made within a risk management process. It consists of the identification of hazards and the analysis and evaluation of risks associated with exposure to those hazards. [IPEC].
84. **sampling**: Operations designed to obtain a representative portion of a pharmaceutical starting material based on an appropriate statistical procedure, for a defined purpose, e.g. acceptance of consignments, batch release, etc..

85. **secondary reference standard**: A substance of established quality and purity, as shown by comparison to a primary reference standard, used as a reference standard for routine laboratory analysis. [IPEC].

86. **significant change**: Any change that alters an excipient’s physical, chemical, or microbiological property from the norm, or that is likely to alter the excipient’s performance in the dosage form.

87. **solvent**: An inorganic or organic liquid used as a vehicle for the presentation of solutions or suspensions in the manufacture of an excipient. [IPEC].

88. **specification**: A list of tests, references to analytical procedures and appropriate acceptance criteria that are numerical limits, ranges or other criteria for the tests described for a material, that a material is required to meet. [IPEC].

89. **stability**: Continued conformance of the excipient to its specifications. [IPEC].

90. **state of control**: A condition in which the set of controls consistently provides assurance of continued process performance and product quality. [IPEC].

91. **subcontractor**: Third party for outsourced work or services which contribute in whole or in part to the manufacture of excipients.

92. **supplier**: Person or company providing pharmaceutical starting materials on request. Suppliers may be distributors, manufacturers, traders, etc..

93. **supply chain**: For the purpose of standards, supply chain is defined as all steps in the entire chain of distribution starting from the point at which an excipient is transferred outside the control of the original manufacturer’s material management system downstream to the final user of the excipient.

94. **top management**: Person or group of people who direct and control an organization at the highest level. The highest level can either be at the site or corporate level and will depend on the way that the quality management system is organized. [IPEC]

95. **traceability**: Ability to determine the history, application or location that is under consideration, for example, origin on materials and parts, processing history or distribution of the product after delivery. [IPEC].

96. **validation**: A documented programme that provides a high degree of assurance that a specific product, method, procedure (i.e. cleaning) or system will consistently produce a result meeting predetermined acceptance criteria. [IPEC].

97. **verification**: The application of methods, procedures, tests and other evaluations, in addition to monitoring, to determine compliance with the GMP principles. [IPEC].
References
The following documents were used in the creation of these standards and provide detailed technical information.


---
